<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Timing of kidney replacement therapy initiation for acute kidney injury - Fayad, AI - 2022 | Cochrane Library</title> <meta content="Timing of kidney replacement therapy initiation for acute kidney injury - Fayad, AI - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010612.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Timing of kidney replacement therapy initiation for acute kidney injury - Fayad, AI - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010612.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010612.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Timing of kidney replacement therapy initiation for acute kidney injury" name="citation_title"/> <meta content="Alicia Isabel Fayad" name="citation_author"/> <meta content="Ricardo Gutierrez Children's Hospital" name="citation_author_institution"/> <meta content="aliciafayad@gmail.com" name="citation_author_email"/> <meta content="Daniel G Buamscha" name="citation_author"/> <meta content="Juan Garrahan Children's Hospital" name="citation_author_institution"/> <meta content="AgustÃ­n Ciapponi" name="citation_author"/> <meta content="Institute for Clinical Effectiveness and Health Policy (IECS-CONICET)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD010612.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010612.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010612.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010612.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Acute Kidney Injury [etiology, therapy]; Critical Illness; Kidney; Length of Stay; *Renal Replacement Therapy [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010612.pub3&amp;doi=10.1002/14651858.CD010612.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="f00EizoA";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010612\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010612\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","pt","ms","ja","hr","fa","pl","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010612.pub3",title:"Timing of kidney replacement therapy initiation for acute kidney injury",firstPublishedDate:"Nov 23, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010612.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010612.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> EspaÃ±ol </option> <option class="content-language-option" data-languagecode="fa" value="fa"> ÙØ§Ø±Ø³Û </option> <option class="content-language-option" data-languagecode="fr" value="fr"> FranÃ§ais </option> <option class="content-language-option" data-languagecode="hi" value="hi"> à¤¹à¤¿à¤¨à¥à¤¦à¥ </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> æ¥æ¬èª </option> <option class="content-language-option" data-languagecode="ko" value="ko"> íêµ­ì´ </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> PortuguÃªs </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Ð ÑÑÑÐºÐ¸Ð¹ </option> <option class="content-language-option" data-languagecode="ro" value="ro"> RomÃ¢nÄ </option> <option class="content-language-option" data-languagecode="ta" value="ta"> à®¤à®®à®¿à®´à¯ </option> <option class="content-language-option" data-languagecode="th" value="th"> à¸ à¸²à¸©à¸²à¹à¸à¸¢ </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> ç¹é«ä¸­æ </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> ç®ä½ä¸­æ </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010612.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010612.pub3/full/es"> EspaÃ±ol </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010612.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010612.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;ÚÚ©ÛØ¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì´ë¡&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en tÃ©rminos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Ø®ÙØ§ØµÙ Ø¨Ù Ø²Ø¨Ø§Ù Ø³Ø§Ø¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© simplifiÃ©&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;LaiÄki saÅ¾etak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;ÃsszefoglalÃ¡s kÃ¶zÃ©rthetÅ nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;ä¸è¬èªè¨³&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì¬ì´ ë§ ìì½&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym jÄzykiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;æ·ºé¡¯ææçå£èªçµè«&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010612.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010612.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010612.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010612.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views:Â </span> <span>4439 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010612.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/appendices#CD010612-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/supinfo/CD010612StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/supinfo/CD010612StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright Â© 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Timing of kidney replacement therapy initiation for acute kidney injury</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information#CD010612-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Alicia Isabel Fayad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information#CD010612-cr-0005">Daniel G Buamscha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information#CD010612-cr-0006">AgustÃ­n Ciapponi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information/en#CD010612-sec-0100">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010612.pub3">https://doi.org/10.1002/14651858.CD010612.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010612-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010612-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010612-abs-0016">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010612-abs-0010">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010612-abs-0013">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010612-abs-0004">íêµ­ì´</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010612-abs-0001" lang="en"> <section id="CD010612-sec-0001"> <h3 class="title" id="CD010612-sec-0001">Background</h3> <p>Acute kidney injury (AKI) is a common condition among patients in intensive care units (ICUs) and is associated with high numbers of deaths. Kidney replacement therapy (KRT) is a blood purification technique used to treat the most severe forms of AKI. The optimal time to initiate KRT so as to improve clinical outcomes remains uncertain. This is an update of a review first published in 2018. </p> <p>This review complements another Cochrane review by the same authors: <i>Intensity of continuous renal replacement therapy for acute kidney injury</i>. </p> </section> <section id="CD010612-sec-0002"> <h3 class="title" id="CD010612-sec-0002">Objectives</h3> <p>To assess the effects of different timing (early and standard) of KRT initiation on death and recovery of kidney function in critically ill patients with AKI. </p> </section> <section id="CD010612-sec-0003"> <h3 class="title" id="CD010612-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplantâs Specialised Register to 4 August 2022 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register, ClinicalTrials and LILACS to 1 August 2022. </p> </section> <section id="CD010612-sec-0004"> <h3 class="title" id="CD010612-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs). We included all patients with AKI in the ICU regardless of age, comparing early versus standard KRT initiation. For safety and cost outcomes, we planned to include cohort studies and nonâRCTs. </p> </section> <section id="CD010612-sec-0005"> <h3 class="title" id="CD010612-sec-0005">Data collection and analysis</h3> <p>Data were extracted independently by two authors. The randomâeffects model was used, and results were reported as risk ratios(RR) for dichotomous outcomes and mean difference(MD) for continuous outcomes, with 95% confidence intervals (CI). </p> </section> <section id="CD010612-sec-0006"> <h3 class="title" id="CD010612-sec-0006">Main results</h3> <p>We included 12 studies enrolling 4880 participants. Overall, most domains were assessed as being at low or unclear risk of bias. </p> <p>Compared to standard treatment, early KRT initiation may have little to no difference on the risk of death at day 30 (12 studies, 4826 participants: RR 0.97,95% CI 0.87 to 1.09; IÂ²= 29%; low certainty evidence), and death after 30 days (7 studies, 4534 participants: RR 0.99, 95% CI 0.92 to 1.07; IÂ² = 6%; moderate certainty evidence). </p> <p>Early KRT initiation may make little or no difference to the risk of death or nonârecovery of kidney function at 90 days (6 studies, 4011 participants: RR 0.91, 95% CI 0.74 to 1.11; IÂ² = 66%; low certainty evidence); CIs included both benefits and harms. </p> <p>Low certainty evidence showed early KRT initiation may make little or no difference to the number of patients who were free from KRT (10 studies, 4717 participants: RR 1.07, 95% CI 0.94 to1.22; IÂ² = 55%) and recovery of kidney function among survivors who were free from KRT after day 30 (10 studies, 2510 participants: RR 1.02, 95% CI 0.97 to 1.07; IÂ² = 69%) compared to standard treatment. </p> <p>High certainty evidence showed early KRT initiation increased the risk of hypophosphataemia (1 study, 2927 participants: RR 1.80, 95% CI 1.33 to 2.44), hypotension (5 studies, 3864 participants: RR 1.54, 95% CI 1.29 to 1.85; IÂ² = 0%), cardiacârhythm disorder (6 studies, 4483 participants: RR 1.35, 95% CI 1.04 to 1.75; IÂ² = 16%), and infection (5 studies, 4252 participants: RR 1.33, 95% CI 1.00 to 1.77; IÂ² = 0%); however, it is uncertain whether early KRT initiation increases or reduces the number of patients who experienced any adverse events (5 studies, 3983 participants: RR 1.23, 95% CI 0.90 to 1.68; IÂ² = 91%; very low certainty evidence). </p> <p>Moderate certainty evidence showed early KRT initiation probably reduces the number of days in hospital (7 studies, 4589 participants: MDâ2.45 days, 95% CI â4.75 to â0.14; IÂ² = 10%) and length of stay in ICU (5 studies, 4240 participants: MD â1.01 days, 95% CI â1.60 to â0.42; IÂ² = 0%). </p> </section> <section id="CD010612-sec-0007"> <h3 class="title" id="CD010612-sec-0007">Authors' conclusions</h3> <p>Based on mainly low to moderate certainty of the evidence, early KRT has no beneficial effect on death and may increase the recovery of kidney function. Earlier KRT probably reduces the length of ICU and hospital stay but increases the risk of adverse events. </p> <p>Further adequateâpowered RCTs using robust and validated tools that complement clinical judgement are needed to define the optimal time of KRT in critical patients with AKI in order to improve their outcomes. The surgical AKI population should be considered in future research. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010612-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010612-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010612-abs-0017">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010612-abs-0011">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010612-abs-0014">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010612-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD010612-abs-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010612-abs-0008">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010612-abs-0005">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010612-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010612-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010612-abs-0006">PortuguÃªs</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010612-abs-0003">ç¹é«ä¸­æ</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010612-abs-0002" lang="en"> <h3>Timing of initiation of kidney replacement therapy (dialysis) for acute kidney injury</h3> <p><b>What is the issue?</b> </p> <p>Acute kidney injury (AKI) is very common among patients admitted to the intensive care unit (ICU); it is associated with high death rates and is characterised by the rapid loss of kidney function. Patients with AKI show increased levels of serum uraemic toxins (creatinine and urea), serum potassium and metabolic acids, accumulation of fluid and, in most cases, a reduction in urine output. In this population, these chemicals and fluid overload are related to increased rates of death. Theoretically, early removal of toxins and excess fluid from the bloodstream might improve patient outcomes (such as death rate and recovery of kidney function). </p> <p>Kidney replacement therapy (KRT), also known as dialysis, is a blood purification technique that enables the removal of excess fluid and toxins. KRT involves blood being diverted from the patient via a catheter (a hollow, flexible tube placed into a vein) through a filtering system which removes excess fluid and toxins; purified blood is then returned to the patient via the catheter. Early initiation of KRT improves the removal of toxins and excess fluid. </p> <p>The aim of this review was to investigate the effect of the different timing of KRT initiation (early or standard) on death, recovery of kidney function, and adverse events in people with AKI who are critically ill. </p> <p><b>What did we do?</b> </p> <p>We searched the literature up until 4 August 2022 and identified 12 studies enrolling 4880 critically ill patients with AKI that were evaluated in this review. </p> <p><b>What did we find?</b> </p> <p>Compared to standard, early KRT initiation may have no benefits on death; however, may increase recovery of kidney function and probably reduces the number of days in ICU and hospital stay, but increases the risk of adverse events in patients with AKI in intensive care units. Nevertheless, regarding death and recovery of kidney function, early KRT initiation showed a range of values that included benefits as well as harms. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010612-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010612-sec-0081"></div> <h3 class="title" id="CD010612-sec-0082">Implications for practice</h3> <section id="CD010612-sec-0082"> <p>Earlier KRT may have little to no difference to death at day 30 or recovery of kidney function, although in both results, the CIs included clinical benefits and harm. </p> <p>Earlier KRT initiation probably reduces ICU and hospital length of stay. Nevertheless, an increased risk of adverse events was observed when compared to a later KRT strategy. </p> <p>The absence of highâquality evidence of efficacy and the possibility of increased adverse events do not support the routine use of early KRT in critically ill patients with AKI. </p> <p>These results do not minimise the importance of the timing of KRT in this population but rather reinforce the need to better understand in what cases earlier initiation translates into improved patient outcomes. Minimal standards for the initiation of KRT appear to have been identified in different guidelines (<a href="./references#CD010612-bbs2-0125" title="KDIGO. Dialysis interventions for treatment of AKI. Kidney International - Supplement2012;2(1):89-115. [PMID: 25018921]">KDIGO 2012</a>;Â <a href="./references#CD010612-bbs2-0133" title="NICE: National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. Clinical guideline [CG169] Published date: August 2013. www.nice.org.uk/guidance/cg169 (accessed 4 August 2022).">NICE 2013</a>;Â <a href="./references#CD010612-bbs2-0145" title="VinsonneauC , Allian-LaunayE , BlayauC , DarmonM , DucheyronD , GaillotT , et al. Renal replacement therapy in adult and pediatric intensive care: Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD). Annals of Intensive Care2015;5(1):58. [MEDLINE: 26714808]">Vinsonneau 2015</a>); however, these approaches provide an incomplete assessment of the optimal timing of KRT. </p> <p>Recent RCTs that investigated timing have provided relevant information and tools which, if added to clinical judgment, will contribute to opportune dialysis interventions and improve the survival of this population. So far, given the lowâmoderate certainty evidence observed in the main outcomes, decisions regarding the optimal timing of KRT should remain based on individual patients' characteristics and clinician judgment. </p> </section> <h3 class="title" id="CD010612-sec-0083">Implications for research</h3> <section id="CD010612-sec-0083"> <p>Given the persistently high death rate among critically ill AKI patients, it would be important to accurately determine the effect of timing of KRT on death. In view of the inconsistencies observed in the main outcomes and the inability to assess all possible causes of heterogeneity, it would be advisable to perform a propensityâbased analysis between patients in the early strategy and those who did not receive KRT in the standard group to define whether these patients could have had a better outcome (<a href="./references#CD010612-bbs2-0105" title="BouchardJ , CutterG , MehtaR . Timing of Initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]">Bouchard 2020</a>)<i>.</i> In addition, KRT intensity during therapy needs to be rigorously evaluated. </p> <p>Although recent studies would seem to favour delayed KRT initiation, there are likely to be limited to how long KRT can be safely delayed. However, the optimal point in time beyond which the benefits of KRT can be maintained is not known. Therefore, adequatelyâpowered RCTs should include appropriate and reproducible criteria to define the optimal time of KRT are needed. At present, five ongoing RCTs (<a href="./references#CD010612-bbs2-0098" title="ChenWY , CaiLH , ZhangZH , TaoLL , WenYC , LiZB , et al. The timing of continuous renal replacement therapy initiation in sepsis-associated acute kidney injury in the intensive care unit: the CRTSAKI Study (Continuous RRT Timing in Sepsis-associated AKI in ICU): study protocol for a multicentre, randomised controlled trial. BMJ Open2021;11(2):e040718. [MEDLINE: 33608398]">CRTSAKI 2021</a>;Â <a href="./references#CD010612-bbs2-0099" title="MaiwallR , NaikV , SinhaSK , PandeA , JagdishRK , RajanV , et al. Early versus late sustained low efficiency dialysis in critically ill cirrhotics with septic shock and acute kidney injury-interim analysis of an open label randomized controlled trial-NCT02937961 [abstract NÂº156]. Hepatology2018;68(Suppl 1):98A. [EMBASE: 624564418]">Maiwall 2018</a>;Â <a href="./references#CD010612-bbs2-0100" title="HongS . Early continuous renal replacement therapies (CRRT) in patients with severe sepsis or septic shock with acute kidney injury. www.clinicaltrials.gov/ct2/show/NCT00837057 (first received 5 February 2009). ">NCT00837057</a>;Â <a href="./references#CD010612-bbs2-0101" title="MaiwallR . On demand versus protocol-guided renal replacement therapy for management of stage 3 acute kidney injury in patients with cirrhosis [.]. www.clinicaltrials.gov/show/NCT02937935 (first received 19 October 2016). ">NCT02937935</a>;Â <a href="./references#CD010612-bbs2-0102" title="MaiwallR . . [Early versus late CRRT (continuous renal replacement therapy) in ACLF (acute on chronic liver failure) patients with septic shock and AKI (acute kidney injury) - a randomised controlled trial]. www.clinicaltrials.gov/show/NCT03343340 (first received 17 November 2017). ">NCT03343340</a>) in this area will provide more answers that will guide clinical practice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010612-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010612-sec-0008"></div> <div class="table" id="CD010612-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Early versus standard initiation of kidney replacement therapy (KRT) in patients with acute kidney injury (AKI)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Early versus standard initiation of KRT in patients with AKI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI<br/><b>Setting:</b> intensive care unit<br/><b>Intervention:</b> early initiation<br/><b>Comparison:</b> standard initiation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants (RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard initiation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with early initiation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death at day 30</b><br/>Â  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>385 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>12 fewer per 1000<br/>(50 fewer to 35 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.97<br/>(0.87 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4826 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death after 30 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>457 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 fewer per 1000<br/>(37 fewer to 32 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.99<br/>(0.92 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4534 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death or nonârecovery of kidney function</b> </p> <p><b>Time frame: day 90</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>468 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>42 fewer per 1000<br/>(122 fewer to 51 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.91<br/>(0.74 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4011(6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recovery of kidney function</b> </p> <p><b>Patients free from KRT according to ITT analysis (all patients)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>493 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 more per 1000<br/>(30 fewer to 108 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.07<br/>(0.94 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4717 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: hypophosphataemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>42 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 more per 1000<br/>(14 more to 61 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.80<br/>(1.33 to 2.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2927 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ââââ<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>81 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>44 more per 1000<br/>(23 more to 69 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.54<br/>(1.29 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3864 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ââââ<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: cardiacârhythm disorder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>54 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19 more per 1000<br/>(2 more to 41 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.35<br/>(1.04 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4483 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ââââ<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 more per 1000<br/>(0 fewer to 25 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.33<br/>(1.00 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4252 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of stay in ICU</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Mean length of stay in ICU was 1.01 days less with early initiation (1.6 less to 0.42 less) compared to standard initiation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4240 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of stay in hospital</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean length of stay in hospital was 2.45 days less with early initiation (4.75 less to 0.14 less) compared to standard initiation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4589 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Imprecision: due to the CI crossed the threshold for clinically meaningful effects </p> <p><sup>2</sup> Inconsistency: due to heterogeneity </p> <p><sup>3</sup> Indirectness: critically ill patients with AKI in RKT have high shortâterm risk of death; death is a competing end point for kidney recovery at day 90 </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010612-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Subgroup analyses: early versus standard initiation of kidney replacement therapy (KRT) in patients with acute kidney injury (AKI)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Early versus standard initiation of KRT in patients with AKI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI<br/><b>Setting:</b> intensive care unit<br/><b>Intervention:</b> early initiation<br/><b>Comparison:</b> standard initiation </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants (RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with standard initiation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk difference with early initiation</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death by AKI aetiology: nonâsurgical causes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>383 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 more per 1000<br/>(23 fewer to 34 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/>(0.94 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4461 (9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death by AKI aetiology: surgical causes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>408 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>143 fewer per 1000<br/>(282 fewer to 147 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/>(0.31 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kidney recovery function</b> <b>by KRT: continuous KRT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>355 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>149 more per 1000<br/>(4 fewer to 365 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.42<br/>(0.99 to 2.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>583 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kidney recovery function</b> <b>by KRT: continuous and intermittent KRT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>520 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>21 fewer per 1000<br/>(47 fewer to 10 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/>(0.91 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4134 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>KRT</b>: kidney replacement therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Imprecision: due to the CI crossed the threshold for clinically meaningful effects </p> <p><sup>2</sup> Inconsistency: due to heterogeneity </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010612-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010612-sec-0009"></div> <section id="CD010612-sec-0010"> <h3 class="title" id="CD010612-sec-0010">Description of the condition</h3> <p>Acute kidney injury (AKI) is a complex clinical entity characterised by an abrupt decline in kidney function (<a href="./references#CD010612-bbs2-0130" title="MehtaRL , KellumJA , ShahSV , MolitorisBA , RoncoC , WarnockDG , et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical Care (London, England)2007;11(2):R31. [MEDLINE: 17331245]">Mehta 2007</a>). AKI incidence among adults admitted to intensive care units (ICUs) ranges fromÂ 5% to 20% (<a href="./references#CD010612-bbs2-0124" title="JoannidisM , MetnitzPG . Epidemiology and natural history of acute renal failure in the ICU. Critical Care Clinics2005;21(2):239â49. [MEDLINE: 15781160]">Joannidis 2005</a>); in children, the incidence is 10% (<a href="./references#CD010612-bbs2-0137" title="SchneiderJ , KhemaniR , GrushkinC , BartR . Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit. Critical Care Medicine2010;38(3):933-9. [MEDLINE: 20124891]">Schneider 2010</a>). Despite its potential to be reversed, AKI is associated with high rates of morbidity and death (<a href="./references#CD010612-bbs2-0103" title="BagshawSM , GeorgeC , BellomoR , ANZICS Database Management Committee. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Critical Care (London, England)2007;11(3):R68. [MEDLINE: 17588270]">Bagshaw 2007</a>). Kidney replacement therapy (KRT) has become a form of kidney support for critically ill patients with AKI (<a href="./references#CD010612-bbs2-0146" title="WaldR , McArthurE , AdhikariNK , BagshawSM , BurnsKE , GargAX , et al. Changing incidence and outcomes following dialysis-requiring acute kidney injury among critically ill adults: a population-based cohort study. American Journal of Kidney Diseases2015;65(6):870-7. [MEDLINE: 25533599]">Wald 2015</a>). Despite advances in clinical care and KRT, the presence of AKI in the ICU setting is associated with poor prognosis and requires significant healthcare resources (<a href="./references#CD010612-bbs2-0142" title="SutherlandSM , ZappitelliM , AlexanderSR , ChuaAN , BrophyPD , BunchmanTE , et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. American Journal of Kidney Diseases2010;55(2):316â25. [MEDLINE: 20042260]">Sutherland 2010</a>;Â <a href="./references#CD010612-bbs2-0144" title="UchinoS , KellumJA , BellomoR , DoigGS , MorimatsuH , MorgeraS , et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA2005;294(7):813-8. [MEDLINE: 16106006]">Uchino 2005</a>).Â  </p> </section> <section id="CD010612-sec-0011"> <h3 class="title" id="CD010612-sec-0011">Description of the intervention</h3> <p>KRT is an extracorporeal blood purification therapy intended to support impaired kidney function. We included the following KRT modalities: Continuous KRT (CKRT) slowly removes fluid (<a href="./references#CD010612-bbs2-0115" title="FolandJA , FortenberryJD , WarshawBL , PettignanoR , MerrittRK , HeardML , et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Critical Care Medicine2004;32(8):1771â6. [MEDLINE: 15286557]">Foland 2004</a>;Â <a href="./references#CD010612-bbs2-0118" title="GibneyN , CerdaJ , DavenportA , RamirezJ , SingbartlK , LeblancM , et al. Volume management by renal replacement therapy in acute kidney injury. International Journal of Artificial Organs2008;31(2):145-55. [MEDLINE: 18311730]">Gibney 2008</a>;Â <a href="./references#CD010612-bbs2-0119" title="GoldsteinSL , CurrierH , GrafJM , CosioCC , BrewerED , SachdevaR . Outcome in children receiving continuous venovenous hemofiltration. Pediatrics2001;107(6):1309-12. [MEDLINE: 11389248]">Goldstein 2001</a>) and high to small molecular weight solutes efficiently over prolonged periods (<a href="./references#CD010612-bbs2-0106" title="BrunnetS , LeblancM , GeadahD , ParentD , CourteauS , CardinalJ . Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. American Journal of Kidney Diseases1999;34(3):486â92. [MEDLINE: 10469859]">Brunnet 1999</a>;Â <a href="./references#CD010612-bbs2-0109" title="ClarkWR , RoncoC . CRRT efficiency and efficacy in relation to solute size. Kidney International - Supplement1999;72:S3-7. [MEDLINE: 10560796]">Clark 1999</a>;Â <a href="./references#CD010612-bbs2-0127" title="LiaoZ , ZhangW , HardyPA , PohCK , HuangZ , KrausMA , et al. Kinetic comparison of different acute dialysis therapies. Artificial Organs2003;27(9):802â7. [MEDLINE: 12940902]">Liao 2003</a>;Â <a href="./references#CD010612-bbs2-0141" title="SieberthHG , StummvollHK , Kierdoff H (editors). Continuous extracorporeal treatment in multiple organ dysfunction syndrome: 3rd International Conference on Continuous Hemofiltration. Vienna, July 8, 1994 (Contributions to Nephrology). Vol. 116. Basal: Karger, 1995.">Sieberth 1995</a>), and confers beneficial haemodynamic stability effects. CKRT modalities are defined by their main solute clearance mechanism. These are convection (continuous venovenous haemofiltration (CVVHF), diffusion (continuous venovenous haemodialysis (CVVHD), or a combination of both convection and diffusion (continuous venovenous haemodiafiltration, CVVHDF) (<a href="./references#CD010612-bbs2-0134" title="PalevskyPM , BunchmanT , TettaC . The Acute Dialysis Quality Initiative--part V: operational characteristics of CRRT. Advances in Renal Replacement Therapy2002;9(4):268â72. [MEDLINE: 12382230]">Palevsky 2002</a>). The intermittent KRT (IKRT) removes fluid and lower molecular weight solutes over a short period of time (sessions of three to five hours), two or three times a week. Diffusion is the main solute clearance mechanism. These are intermittent haemodialysis (IHD), intermittent haemofiltration (IHF), intermittent haemodiafiltration (IHDF), and intermittent highâflux dialysis (IHFD). The hybrid therapies, also known as prolonged IKRTs, such as sustained lowâefficiency dialysis (SLED) and extendedâduration dialysis (EDD); provides KRT for an extended period of time (six to 18 hours), at least three times/week (<a href="./references#CD010612-bbs2-0111" title="EdreesF , LiT , VijayanA . Prolonged intermittent renal replacement therapy. Advances in Chronic Kidney Disease2016;23(3):195-202. [MEDLINE: 27113696]">Edrees 2016</a>); includes both convective (i.e. haemofiltration) and diffusive (i.e. haemodialysis) therapies, depending on the method of solute removal (<a href="./references#CD010612-bbs2-0128" title="MarshallMR , GolperTA . Low-efficiency acute renal replacement therapy: role in acute kidney injury. Seminars in Dialysis2011;24(2):142-8. [MEDLINE: 21517979]">Marshall 2011</a>). Peritoneal dialysis modality was not included. </p> <p>Timing of KRT initiation is generally related to "when to start renal support in critically ill patients with AKI". A number of organisations have published practice guidelines that include statements on the timing of KRT initiation in ICU settings. The Kidney Disease Improving Global Outcomes (<a href="./references#CD010612-bbs2-0125" title="KDIGO. Dialysis interventions for treatment of AKI. Kidney International - Supplement2012;2(1):89-115. [PMID: 25018921]">KDIGO 2012</a>), the National Institute for Health and Care Excellence (<a href="./references#CD010612-bbs2-0133" title="NICE: National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. Clinical guideline [CG169] Published date: August 2013. www.nice.org.uk/guidance/cg169 (accessed 4 August 2022).">NICE 2013</a>) and the French Intensive Care Society (<a href="./references#CD010612-bbs2-0145" title="VinsonneauC , Allian-LaunayE , BlayauC , DarmonM , DucheyronD , GaillotT , et al. Renal replacement therapy in adult and pediatric intensive care: Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD). Annals of Intensive Care2015;5(1):58. [MEDLINE: 26714808]">Vinsonneau 2015</a>) have published practice guidelines that include statements on the timing of KRT initiation in ICU settings. There has been consensus on the standard initiation criteria: when lifeâthreatening changes in fluid, electrolytes and acidâbased balance exist according to different guidelines; however, none of the recommendations have been graded. Unfortunately, there has been little consensus on the early beginning of KRT in ICU patients with AKI. Some published studies have used urine output and serum creatinine (SCr) (<a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>) or urine output and creatinine clearance (CrCl) (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>) as surrogate criteria of early initiation. Other authors have considered time to ICU admission (<a href="./references#CD010612-bbs2-0104" title="BagshawSM , UchinoS , BellomoR , MorimatsuH , MorgeraS , SchetzM , et al. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. Journal of Critical Care2009;24(1):129-40. [MEDLINE: 19272549]">Bagshaw 2009</a>), time to fulfilling AKI stage 2 within 8 hr (<a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>) or within 12 hr using a novel kidney damage biomarker neutrophil gelatinaseâassociated lipocalin (NGAL) (<a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>), and time to fulfilling AKI stage 3 (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>). With poor agreement (expert opinion),Â <a href="./references#CD010612-bbs2-0133" title="NICE: National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. Clinical guideline [CG169] Published date: August 2013. www.nice.org.uk/guidance/cg169 (accessed 4 August 2022).">NICE 2013</a>Â andÂ <a href="./references#CD010612-bbs2-0145" title="VinsonneauC , Allian-LaunayE , BlayauC , DarmonM , DucheyronD , GaillotT , et al. Renal replacement therapy in adult and pediatric intensive care: Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD). Annals of Intensive Care2015;5(1):58. [MEDLINE: 26714808]">Vinsonneau 2015</a>Â also published possible indicators for early kidney support therapy, e.g. weight "gain less than 10%, urea less than 25 mmol/litre and oliguria 0.5 ml/kg/hr or less for at least 24 hours" or "KDIGO AKI stage 2 or within 24 hr after the onset of AKI of which reversibility seems unlikely, respectively". In our review, we will assign definitions given in included studies in relation to early and standard KRT initiation. </p> </section> <section id="CD010612-sec-0012"> <h3 class="title" id="CD010612-sec-0012">How the intervention might work</h3> <p>A hypothesis that the timing of KRT commencement may affect survival emerged from animal and human studies over the past decade. Animal studies investigating sepsis (<a href="./references#CD010612-bbs2-0131" title="MinkSN , JhaP , WangR , YangJ , BoseD , JacobsH , et al. Effect of continuous arteriovenous hemofiltration combined with systemic vasopressor therapy on depressed left ventricular contractility and tissue oxygen delivery in canine Escherichia coli sepsis. Anesthesiology1995;83(1):178-90. [MEDLINE: 7604996]">Mink 1995</a>) and pancreatitis (<a href="./references#CD010612-bbs2-0150" title="YekebasEF , StrateT , ZolmajdS , EisenbergerCF , ErbersdoblerA , SaalmullerA , et al. Impact of different modalities of continuous venovenous hemofiltration on sepsis-induced alterations in experimental pancreatitis. Kidney International2002;62(5):1806-18. [MEDLINE: 12371983]">Yekebas 2002</a>) suggested beneficial effects on physiologic and clinical endpoints when haemofiltration was started early, simultaneously or two hours after injury. Several observational studies investigated the effect of timing in patients with AKI;Â <a href="./references#CD010612-bbs2-0143" title="TeschanPE , BaxterCR , OâBrienTF , FreyhofJN , HallWH . Prophylactic haemodialysis in the treatment of acute renal failure. Annals of Internal Medicine1960;53:992-1016. [MEDLINE: 13776062]">Teschan 1960</a>Â reported improved survival rates relating to KRT timing in patients commencing dialysis with low blood urea nitrogen;Â <a href="./references#CD010612-bbs2-0117" title="GettingsLG , ReynoldsHN , ScaleaT . Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late. Intensive Care Medicine1999;25(8):805â13. [MEDLINE: 10447537]">Gettings 1999</a>Â indicated improved survival in early haemofiltration patients with AKI related to trauma, the same was found in patients with AKI post cardiac surgery (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0110" title="DemirkilicU , KuralayE , YenicesuM , CaglarK , OzBS , CingozF , et al. Timing of replacement therapy for acute renal failure after cardiac surgery. Journal of Cardiac Surgery2004;19(1):17â20. [MEDLINE: 15108784]">Demirkilic 2004</a>;Â <a href="./references#CD010612-bbs2-0112" title="ElahiMM , LimMY , JosephRN , DhannapuneniRR , SpytTJ . Early hemofiltration improves survival in post-cardiotomy patients with acute renal failure. European Journal of Cardiothoracic Surgery2004;26(5):1027â31. [MEDLINE: 15519198]">Elahi 2004</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>). Randomised controlled trials (RCTs) found patients with pancreatitis had significantly better survival in patients who received early haemofiltration (within 48 hours after the onset of abdominal pain) than in the group with late haemofiltration (96 hours after the onset of abdominal pain (<a href="./references#CD010612-bbs2-0123" title="JiangHL , XueWJ , LiDQ , YinAP , XinX , LiCM , et al. Influence of continuous venovenous hemofiltration on the course of acute pancreatitis. World Journal of Gastroenterology2005;11(31):4815-21. [MEDLINE: 16097050]">Jiang 2005</a>), while other RCTs failed to demonstrate these advantages (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>). </p> </section> <section id="CD010612-sec-0013"> <h3 class="title" id="CD010612-sec-0013">Why it is important to do this review</h3> <p>Studies assessing KRT timing (early versus standard) have reported inconsistent results: earlier studies indicated significant improvements in survival and kidney function recovery, yet others, including RCTs and metaâanalyses, did not find these benefits. We investigated the relationship between different timing of KRT initiation and clinical outcomes for critical patients with AKI. Review evidence could have direct relevance to guide clinical practice. </p> <p>This review complements another Cochrane systematic review by the same authors: <i>Intensity of continuous renal replacement therapy for acute kidney injury</i> (<a href="./references#CD010612-bbs2-0114" title="FayadAI , BuamschaDG , CiapponiA . Intensity of continuous renal replacement therapy for acute kidney injury. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD010613. [DOI: 10.1002/14651858.CD010613]">Fayad 2016</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010612-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010612-sec-0014"></div> <p>To assess the effects of different timing (early and standard) of KRT initiation on death and recovery of kidney function in critically ill patients with AKI. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010612-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010612-sec-0015"></div> <section id="CD010612-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010612-sec-0017"> <h4 class="title">Types of studies</h4> <p>All RCTs looking at KRT modalities for people with AKI in ICU settings were eligible for inclusion. For outcomes such as safety and costs, nonâRCTs and cohort studies were also planned to be included if sufficiently high quality, sampling was clearly described, patients characterised, proportions of patients experiencing any adverse events or who dropped out because of adverse events were adequately reported, coâinterventions were described, and at least 80% of patients included were analysed after treatment. </p> </section> <section id="CD010612-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD010612-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>We included all patients with AKI in the ICU being treated with KRT regardless of age and gender. We assigned AKI definitions cited by the included studies. </p> </section> <section id="CD010612-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p>We excluded patients who received dialysis treatment before admission to ICU, patients admitted for drug overdose (doses exceeding therapeutic requirements), or with acute poisoning (all toxins). </p> </section> </section> <section id="CD010612-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We compared early (intervention group) versus standard (control) initiation in CKRT and IKRT. We excluded the peritoneal dialysis modality. The criteria of time were defined as published in the original publications. </p> </section> <section id="CD010612-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD010612-sec-0023"> <h5 class="title">Primary outcomes</h5> <section id="CD010612-sec-0024"> <h6 class="title">Death</h6> <p> <ul id="CD010612-list-0001"> <li> <p>Death from any cause at days 7, 15, 30, 60 and 90</p> </li> <li> <p>Death or nonârecovery of kidney function at day 90.</p> </li> </ul> </p> </section> <section id="CD010612-sec-0025"> <h6 class="title">Recovery of kidney function</h6> <p> <ul id="CD010612-list-0002"> <li> <p>Number free of KRT according to intentionâtoâtreat analysis</p> </li> <li> <p>Number free of KRT according to intentionâtoâtreat analysis at days 30, 60 and 90.</p> </li> </ul> </p> </section> </section> <section id="CD010612-sec-0026"> <h5 class="title">Secondary outcomes</h5> <section id="CD010612-sec-0027"> <h6 class="title">Adverse events</h6> <p> <ul id="CD010612-list-0003"> <li> <p>Number experiencing any adverse events</p> </li> <li> <p>Number who dropped out because of any adverse events (technique or patientâdependent factors) </p> </li> <li> <p>Number with interventionârelated complications (e.g. disequilibrium, hypokalaemia, hypophosphataemia, hypocalcaemia, bleeding, hypotension) </p> </li> <li> <p>Number with catheterârelated complications.</p> </li> </ul> </p> <p>We looked for differences in overall dropâout rates and any adverse effects by type (mild or severe). We defined adverse events severity where medical therapeutic interventions were implied in reporting. Withdrawals due to protocol violation or loss to followâup were not included in counts of adverse events. </p> </section> <section id="CD010612-sec-0028"> <h6 class="title">Length of stay</h6> <p> <ul id="CD010612-list-0004"> <li> <p>Days in hospital</p> </li> <li> <p>Days in ICU.</p> </li> </ul> </p> </section> <section id="CD010612-sec-0029"> <h6 class="title">Cost</h6> <p>We planned to assess the costs of KRT modalities, including:</p> <p> <ul id="CD010612-list-0005"> <li> <p>Type and number of dialyser filters</p> </li> <li> <p>Use or no use of anticoagulation</p> </li> <li> <p>Types of anticoagulation and anticoagulants</p> </li> <li> <p>Use of replacement fluid</p> </li> <li> <p>Number of days on KRT.</p> </li> </ul> </p> <p>All costs were to be reported in international monetary units.</p> <p> <ul id="CD010612-list-0006"> <li> <p>Cost/day of KRT</p> </li> <li> <p>Length of hospital stay with KRT</p> </li> <li> <p>Length of ICU stay with KRT.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD010612-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010612-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Kidney and Transplant Specialised Register to 4 August 2022 through contact with the Information Specialist using search terms relevant to this review. The Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD010612-list-0007"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidneyârelated journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP). Search Portal and ClinicalTrials.gov. </p> </li> </ol> </p> <p>Studies contained in the Specialised Register were identified through search strategies for CENTRAL, MEDLINE and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>SeeÂ <a href="./appendices#CD010612-sec-0087">Appendix 1</a>Â for search terms and strategies used for this review.<br/>Â  </p> </section> <section id="CD010612-sec-0032"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD010612-list-0008"> <li> <p>LILACS (Latin American and Caribbean Health Sciences) (from March 1980 to August 2022)</p> </li> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD010612-sec-0033"> <h3 class="title" id="CD010612-sec-0033">Data collection and analysis</h3> <section id="CD010612-sec-0034"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies with potential relevance to the review. Titles and abstracts were screened independently by two authors who discarded studies that were not applicable; however, studies and reviews that could include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which satisfied the inclusion criteria. </p> </section> <section id="CD010612-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors (AF, DB) using standard data extraction forms. Studies reported in nonâEnglish language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together, and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. We resolved any discrepancies by discussion (AF, DB, AC). </p> </section> <section id="CD010612-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed using the risk of bias assessment tool (<a href="./references#CD010612-bbs2-0122" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>) (seeÂ <a href="./appendices#CD010612-sec-0088">Appendix 2</a>). </p> <p> <ul id="CD010612-list-0009"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD010612-list-0010"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> </section> <section id="CD010612-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>For normally distributed outcomes, we calculated summary estimates of treatment effects using the inverse variance method. For dichotomous outcomes (death, kidney recovery and adverse events), results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (length of stay, cost), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales were used. The results were interpreted taking into account the size of the effect (magnitude or importance) (seeÂ <a href="./references#CD010612-bbs2-0108" title="CKT. Reporting results in CKT reviews (using material adapted from EPOC and CCCR). www.kidneyandtransplant.cochrane.org/sites/kidneyandtransplant.cochrane.org/files/public/uploads/Resources/reporting_results_in_ckt_reviews_2017.pdf (date accessed 4 August 2022).">CKT 2017</a>;Â <a href="./references#CD010612-bbs2-0113" title="Effective Practice of Care. Interpreting statistical significance. www.epoc.cochrane.org (last accessed prior to 26 November 2018).">EPOC 2013</a>). </p> </section> <section id="CD010612-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participants of each arm (early or standard KRT initiation) that died, recovered of kidney function, the length of ICU and Hospital stay, or had adverse events. </p> </section> <section id="CD010612-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence (e.g. emailing to the corresponding author), and any relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened, randomised patients, as well as intentionâtoâtreat, asâtreated and perâprotocol population, was carefully performed. Attrition rates, for example, dropâouts, losses to followâup and withdrawals, were investigated. Issues of missing data and imputation methods (e.g. lastâobservationâcarriedâforward) were critically appraised (<a href="./references#CD010612-bbs2-0122" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD010612-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a ChiÂ² test on Nâ1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the IÂ² test (<a href="./references#CD010612-bbs2-0121" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). IÂ² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD010612-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, funnel plots were to be used to assess the potential existence of small study bias (<a href="./references#CD010612-bbs2-0122" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD010612-sec-0042"> <h4 class="title">Data synthesis</h4> <p>Data were to be pooled using the randomâeffects model; however, the fixedâeffect model was also used to ensure the robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD010612-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was used to explore possible sources of heterogeneity (such as intervention, parameters to define early or standard initiation, participant and study quality). Heterogeneity among participants could relate to age, gender, fluid overload (&lt; 10% and &gt; 10% in body weight relative to baseline), and timing of KRT for AKI in homogenous subpopulations such as cardiac surgery or sepsis patients, effects of early initiation on the severity of illness. We used appropriate scores of illness severity, such as Pediatric Risk of Mortality (PRISM), Pediatric Index of Mortality (PIM), Acute Physiology and Chronic Health Evaluation (APACHE), Sequential Organ Failure Assessment (SOFA), and Cleveland Clinic ICU Acute Renal Failure (CCF). Adverse effects were tabulated and assessed using descriptive techniques. Where possible, the risk difference with 95% CI was calculated for each adverse effect, either compared with no treatment or another agent. In addition, where we identified important statistical or clinical heterogeneity, we performed metaâregression in order to explore the possible causes. </p> </section> <section id="CD010612-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to explore the influence of the following factors on effect size: </p> <p> <ul id="CD010612-list-0011"> <li> <p>Repeating the analysis, excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking account of the risk of bias</p> </li> <li> <p>Repeating the analysis, excluding any very long or large studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, the language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> </section> <section id="CD010612-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes. The 'Summary of findings' tables include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD010612-bbs2-0120" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>;Â <a href="./references#CD010612-bbs2-0108" title="CKT. Reporting results in CKT reviews (using material adapted from EPOC and CCCR). www.kidneyandtransplant.cochrane.org/sites/kidneyandtransplant.cochrane.org/files/public/uploads/Resources/reporting_results_in_ckt_reviews_2017.pdf (date accessed 4 August 2022).">CKT 2017</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of the withinâstudy risk of bias (methodological quality), directness of evidence, heterogeneity, the precision of effect estimates and risk of publication bias (<a href="./references#CD010612-bbs2-0139" title="SchÃ¼nemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schunemann 2021b</a>). Summary of findings table 1 summarizes the main findings for the comparison "Early versus standard initiation of KRT for acute kidney injury". We presented the following outcomes. </p> <p> <ul id="CD010612-list-0012"> <li> <p>Death until day 30 postârandomisation</p> </li> <li> <p>Death after day 30 postârandomisation</p> </li> <li> <p>Death or nonârecovery of kidney function at 90 days</p> </li> <li> <p>Kidney function recovery: number of patients free from KRT according to intentionâtoâtreat analysis (all patients) </p> </li> <li> <p>Number of patients with hypotension, hypophosphataemia, cardiacârhythm disorder and infections </p> </li> <li> <p>Length of ICU and hospital stay</p> </li> <li> <p>Subgroup analysis: death in patients who start KRT according to aetiology of AKI, recovery of kidney function by KRT modality. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010612-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010612-sec-0046"></div> <section id="CD010612-sec-0047"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010612-sec-0106" title="">Characteristics of included studies</a>; <a href="./references#CD010612-sec-0107" title="">Characteristics of excluded studies</a>; <a href="./references#CD010612-sec-0108" title="">Characteristics of ongoing studies</a> </p> <section id="CD010612-sec-0048"> <h4 class="title">Results of the search</h4> <p>Our 2018 review identified five studies (10 reports, 1084 participants) (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>), 84 excluded studies (198 reports), one ongoing study, and one study was awaiting classification. </p> <p>For this 2022 review update, we searched Cochrane Kidney and Transplantâs Specialised Register, LILACS and undertook additional handsearching and identified 64 new reports of 12 studies. Six new studies (10 reports) (<a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>), and one study, previously awaiting classification (one new report) (<a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>), have been included in this update. Four new ongoing studies (four reports) were identified (<a href="./references#CD010612-bbs2-0099" title="MaiwallR , NaikV , SinhaSK , PandeA , JagdishRK , RajanV , et al. Early versus late sustained low efficiency dialysis in critically ill cirrhotics with septic shock and acute kidney injury-interim analysis of an open label randomized controlled trial-NCT02937961 [abstract NÂº156]. Hepatology2018;68(Suppl 1):98A. [EMBASE: 624564418]">Maiwall 2018</a>;Â <a href="./references#CD010612-bbs2-0101" title="MaiwallR . On demand versus protocol-guided renal replacement therapy for management of stage 3 acute kidney injury in patients with cirrhosis [.]. www.clinicaltrials.gov/show/NCT02937935 (first received 19 October 2016). ">NCT02937935</a>;Â <a href="./references#CD010612-bbs2-0098" title="ChenWY , CaiLH , ZhangZH , TaoLL , WenYC , LiZB , et al. The timing of continuous renal replacement therapy initiation in sepsis-associated acute kidney injury in the intensive care unit: the CRTSAKI Study (Continuous RRT Timing in Sepsis-associated AKI in ICU): study protocol for a multicentre, randomised controlled trial. BMJ Open2021;11(2):e040718. [MEDLINE: 33608398]">CRTSAKI 2021</a>;Â <a href="./references#CD010612-bbs2-0102" title="MaiwallR . . [Early versus late CRRT (continuous renal replacement therapy) in ACLF (acute on chronic liver failure) patients with septic shock and AKI (acute kidney injury) - a randomised controlled trial]. www.clinicaltrials.gov/show/NCT03343340 (first received 17 November 2017). ">NCT03343340</a>), and one new study (four reports) was excluded (<a href="./references#CD010612-bbs2-0014" title="GaudryS , HajageD , LouisG , QuenotJP , DreyfussD . The AKIKI 2 trial: a case for strategy of initiation instead of timing - Authors' reply. Lancet2021;398(10307):1215-6. [MEDLINE: 34600623]GaudryS , HajageD , Martin-LefevreL , LebbahS , LouisG , MoschiettoS , et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet2021;397(10281):1293-300. [MEDLINE: 33812488]GaudryS , HajageD , Martin-LefevreL , LouisG , MoschiettoS , Titeca-BeauportD , et al. The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial. Trials [Electronic Resource]2019;20(1):726. [MEDLINE: 31843007]GaudryS , HajageD , QuenotJP , LefevreLM , LouisG , GrangeS , et al. The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI 2)-where are we for this multicenter randomised controlled trial? [abstract no:P-109]. Annals of Intensive Care2019;9(Suppl 1):111. [EMBASE: 630113715]JamaleTE . The AKIKI 2 trial: a case for strategy of initiation instead of timing. Lancet2021;398(10307):1215. [MEDLINE: 34600622]">AKIKI 2 2019</a>). We also identified 44 new reports of existing included and excluded studies. SeeÂ <a href="#CD010612-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010612-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart showing number of reports retrieved by database searching and the number of studies included in this review" data-id="CD010612-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart showing number of reports retrieved by database searching and the number of studies included in this review </p> </div> </div> </div> <p>A total of 12 studies (35 reports, 4880 randomised participants) have been included, 85 studies excluded (235 reports), and there are five ongoing studies (five reports) in this 2022 update. </p> </section> <section id="CD010612-sec-0049"> <h4 class="title">Included studies</h4> <p>Twelve studies (4880 participants) were included (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>). </p> <p>Study participants were all admitted to ICU. The mean age was between 62.8 and 69 years, and the proportion of males ranged from 49.6% to 70.4%. Surgery or cardioâsurgery was the primary cause of AKI in three studies (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>) and mixed (medical or surgical) in the other nine studies (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>). </p> <p>All studies were reported between 2002 and 2019. Six were singleâcentre studies (<a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>), and six were multicentre (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>). </p> <p>Eight studies predominantly used CKRT (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>), and four used combined therapies (intermittent and continuous) (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>). </p> <p>All the included studies assessed the effects of timing (early and standard) of KRT initiation on clinical outcomes of critical patients with AKI. InÂ <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>, two of the three arms received the same timing of KRT initiation (early) but differed only in the intensities of continuous therapy. For the purpose of the analysis, we combined these two early treatment arms to create one early arm. </p> <p><a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>Â did not report the treatment allocation of 8/36 participants that did not start the treatment. We assumed that they were evenly distributed among treatment arms (18 participants/arm). Similarly, we assumed that these eight participants had a favourable evolution (none of them died, and all of them recovered). </p> <p>The included studies used a wide spectrum of definitions for early and standard initiation of KRT.Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>Â andÂ <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>Â defined early KRT initiation based on physiologic (urine output) and biochemical parameters (CrCl/SCr, respectively). Four studies defined early as starting KRT within 8 and 12 hours of fulfilling KDIGO stage 2 (<a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>),12 hours of fulfilling KDIGO stage 2â3 (<a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>), 12 hours after the onset of failure stage of RIFLE (<a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>), or within 6 hours of fulfilling KDIGO stage 3 (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>) and AKIN stage 2â3 (<a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>). The other three studies used any KDIGO stage and no response to the furosemide test as criteria of early KRT initiation (<a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>) or an AKI biomarker (e.g. high urinary or serum NGAL) (<a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>). </p> <p>SeeÂ <a href="./references#CD010612-sec-0106" title="">Characteristics of included studies.</a> </p> </section> <section id="CD010612-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded 85 studies (235 records). Studies were excluded for the following reasons:</p> <p> <ul id="CD010612-list-0013"> <li> <p>Two reports inÂ <a href="./references#CD010612-bbs2-0076" title="BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low-intensity and high-intensity continuous renal replacement therapy.[Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34-41. [MEDLINE: 24588434]BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036]BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the Randomized Evaluation of Normal versus Augmented Level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325-34. [MEDLINE: 25171270]BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase-FielitzA , LicariE , et al. Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429-36. [MEDLINE: 23306586]BellomoR , MartenssonJ , KaukonenKM , LoS , GallagherM , CassA , et al. Epidemiology of RBC transfusions in patients with severe acute kidney injury: analysis from the randomized evaluation of normal versus augmented level study. Critical Care Medicine2016;44(5):892-900. [MEDLINE: 26619086]BellomoR , MartenssonJ , LoS , KaukonenKM , CassA , GallagherM , et al. Femoral access and delivery of continuous renal replacement therapy dose. Blood Purification2016;41(1-3):11-7. [MEDLINE: 26485539]BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?Kidney International2006;70(7):1202-4. [MEDLINE: 16988729]CassA , BellomoR , ColeL , FinferS , GallagherM , LoS , et al. Intensity of continuous renal replacement therapy in critically ill patients with severe acute kidney injury [abstract no: O78]. Nephrology2009;14(Suppl 1):A21. FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of replacement therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58-66. [MEDLINE: 19281446]GallagherM , BellomoR , CassA , ColeL , FinferS , LeeJ , et al. Fluid balance and patient outcomes in AKI: analysis of the RENAL study participants [abstract no: 128]. Nephrology2011;16(Suppl 1):57. GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post-RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45-6. [EMBASE: 71377309]GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666]GallagherMP , BellomoR , CassA , ColeL , LeeJY , LoSN , et al. Fluid balance and patient outcomes in AKI: analysis of the RENAL study participants [abstract no: SA-PO2521]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):698A. GallagherMP , BellomoR , CassA , GattasD , LeeJY , LoSN , et al. Long term outcomes of severe AKI: results of the post-RENAL study [abstract no: SA-OR008]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):67A. JunM , BellomoR , CassA , GallagherM , LoS , LeeJ , et al. Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study. Critical Care Medicine2014;42(8):1756-65. [MEDLINE: 24717460]JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29-30. [EMBASE: 71377246]JunM , BellomoR , CassA , GallagherMP , LoSN . Timing of renal replacement therapy and outcomes in critically III patients with acute kidney injury in the randomised evaluation of normal versus augmented level of replacement therapy therapy trial [abstract no: TH-OR038]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):8A. LinJ , GallagherM , BellomoR , DuanM , TrongtrakulK , WangAY , et al. SOFA coagulation score and changes in platelet counts in severe acute kidney injury: Analysis from the randomised evaluation of normal versus augmented level (RENAL) study. Nephrology2019;24(5):518-25. [MEDLINE: 29693303]LinJ , WangY , BellomoR , DuanML , GallagherMP . Sofa coagulation score and patient outcomes in severe acute kidney injury: Analysis from the randomized evaluation of normal versus augmented level (RENAL) study [abstract]. Nephrology2017;22(3):51. [EMBASE: 618236384]LinJ , WangY , BellomoR , DuanML , GallagherMP . Sofa coagulation score and patient outcomes in severe AKI: analysis from the Randomised Evaluation of Normal versus Augmented Level (RENAL) study [abstract no: PUB049]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):976. [EMBASE: 633701676]MuruganR , KertiSJ , ChangCH , GallagherM , ClermontG , PalevskyPM , et al. Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous haemodiafiltration: a secondary analysis of the Randomized Evaluation of Normal vs Augmented Level (RENAL) of Renal Replacement Therapy trial. JAMA Network Open2019;2(6):e195418. [MEDLINE: 31173127]O'BrienZ , CassA , ColeL , FinferS , GallagherM , McArthurC , et al. Higher versus lower continuous renal replacement therapy intensity in critically ill patients with liver dysfunction. Blood Purification2018;45(1-3):36-43. [MEDLINE: 29161684]O'BrienZ , CassA , ColeL , FinferS , GallagherM , McArthurC , et al. Sex and mortality in septic severe acute kidney injury. Journal of Critical Care2019;49:70-6. [MEDLINE: 30388491]RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high-dose versus standard-dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407-16. [MEDLINE: 18856012]RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199-205. [MEDLINE: 19256108]RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement therapy trial. Critical Care Medicine2012;40(6):1753-60. [MEDLINE: 22610181]RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627-38. [MEDLINE: 19846848]RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236]RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19:84. [MEDLINE: 25881576]WangA , LoS , BellomoR , CassA , GallagherM . Ace inhibitor use and AKI outcomes: an analysis of the Randomised Evaluation of Normal vs Augmented Level of replacement therapy (RENAL) trial [abstract no: 104]. Nephrology2013;18(Suppl 1):41. [EMBASE: 71357086]WangAY , BellomoR , CassA , FinferS , GattasD , MyburghJ , et al. Health-related quality of life in survivors of acute kidney injury: The prolonged outcomes study of the Randomized Evaluation of Normal versus Augmented Level replacement therapy study outcomes. Nephrology2015;20(7):492-8. [MEDLINE: 25891297]WangAY , BellomoR , CassA , MyburghJ , FinferS , GattaD , et al. Predictors of health-related quality of life in survivors following acute kidney injury: a secondary analysis of post-renal study outcomes [abstract no: 117]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii107-8. [EMBASE: 71491744]WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin-converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617-22. [MEDLINE: 24894685]WangAY , TrongtrakulK , BellomoR , LiQ , CassA , GallagherM , et al. HMG-CoA reductase inhibitors (statins) and acute kidney injury:a secondary analysis of renal study outcomes. Nephrology2019;24(9):912-8. [MEDLINE: 31058387]WangY , LoSN , GallagherMP , LiQ , CassA , MyburghJA , et al. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independance. [abstract no: SA-OR105]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):86A. XieY , LinJ , GallagherM , BellomoR , WangX , JardineM , et al. Prognostic significance of low level of blood glucose in severe acute kidney injury: A secondary analysis from the RENAL study [abstract NÂº: SP243]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i425. [EMBASE: 622604949]">RENAL 2006</a>Â assessed timing; however, the study design was not randomised (retrospective nested cohort) </p> </li> <li> <p>Five studies did not mandate the presence of AKI (<a href="./references#CD010612-bbs2-0034" title="DurmazI , YagdiT , CalkavurT , MahmudovR , ApaydinAZ , PosaciogluH , et al. Prophylactic dialysis in patients with renal dysfunction undergoing on-pump coronary artery bypass surgery. Annals of Thoracic Surgery2003;75(3):859-64. [MEDLINE: 12645707]">Durmaz 2003</a>;Â <a href="./references#CD010612-bbs2-0044" title="CombesA , BrechotN , AmourJ , CozicN , LebretonG , GuidonC , et al. Early high-volume hemofiltration versus standard care for post-cardiac surgery shock. the HEROICS study. American Journal of Respiratory &amp; Critical Care Medicine2015;192(10):1179-90. [MEDLINE: 26167637]">HEROICS 2015</a>;Â <a href="./references#CD010612-bbs2-0042" title="HanF , SunR , NiY , HuX , ChenX , JiangL , et al. Early initiation of continuous renal replacement therapy improves clinical outcomes in patients with acute respiratory distress syndrome. American Journal of the Medical Sciences2015;349(3):199-205. [MEDLINE: 25494217]">Han 2015</a>;Â <a href="./references#CD010612-bbs2-0055" title="KooJ , YoonJ , OhJ , LeeY , KimS , SeoJ , et al. Prospective evaluation of early continuous venovenous hemofiltration (CVVH) on the outcome in patients with severe sepsis or septic shock [abstract no: F-FC062]. Journal of the American Society of Nephrology2006;17(Abstract):50A. ">Koo 2006</a>;Â <a href="./references#CD010612-bbs2-0070" title="PayenD , MateoJ , CavaillonJM , FraisseF , FloriotC , VicautE , et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Critical Care Medicine2009;37(3):803-10. [MEDLINE: 19237881]">Payen 2009</a>) or ICU stay as inclusion criteria in the early initiation arm (<a href="./references#CD010612-bbs2-0046" title="JamaleTE , HaseNK , KulkarniM , PradeepKJ , KeskarV , JawaleS , et al. Earlier-start versus usual-start dialysis in patients with community-acquired acute kidney injury: a randomized controlled trial. American Journal of Kidney Diseases2013;62(6):1116-21. [MEDLINE: 23932821]">Jamale 2013</a>;Â <a href="./references#CD010612-bbs2-0074" title="PursnaniML , HazraDK , SinghB , PandeyDN . Early haemodialysis in acute tubular necrosis. Journal of the Association of Physicians of India1997;45(11):850-2. [MEDLINE: 11229183]">Pursnani 1997</a>) </p> </li> <li> <p>Two studies did not assess the outcomes of interest to this review (<a href="./references#CD010612-bbs2-0027" title="ColeL , BellomoR , HartG , JournoisD , DavenportP , TippingP , et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Critical Care Medicine2002;30(1):100-6. [MEDLINE: 11902250]">Cole 2002</a>;Â <a href="./references#CD010612-bbs2-0062" title="MissetB , TimsitJF , ChevretS , RenaudB , TamionF , CarletJ . A randomized cross-over comparison of the hemodynamic response to intermittent hemodialysis and continuous hemofiltration in ICU patients with acute renal failure. Intensive Care Medicine1996;22(8):742-6. [MEDLINE: 8880241]">Misset 1996</a>) </p> </li> <li> <p>One study (<a href="./references#CD010612-bbs2-0014" title="GaudryS , HajageD , LouisG , QuenotJP , DreyfussD . The AKIKI 2 trial: a case for strategy of initiation instead of timing - Authors' reply. Lancet2021;398(10307):1215-6. [MEDLINE: 34600623]GaudryS , HajageD , Martin-LefevreL , LebbahS , LouisG , MoschiettoS , et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet2021;397(10281):1293-300. [MEDLINE: 33812488]GaudryS , HajageD , Martin-LefevreL , LouisG , MoschiettoS , Titeca-BeauportD , et al. The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial. Trials [Electronic Resource]2019;20(1):726. [MEDLINE: 31843007]GaudryS , HajageD , QuenotJP , LefevreLM , LouisG , GrangeS , et al. The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI 2)-where are we for this multicenter randomised controlled trial? [abstract no:P-109]. Annals of Intensive Care2019;9(Suppl 1):111. [EMBASE: 630113715]JamaleTE . The AKIKI 2 trial: a case for strategy of initiation instead of timing. Lancet2021;398(10307):1215. [MEDLINE: 34600622]">AKIKI 2 2019</a>) had no early intervention arm </p> </li> <li> <p>The remaining 72 studies did not assess the timing of KRT.</p> </li> </ul> </p> <p>SeeÂ <a href="./references#CD010612-sec-0107" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD010612-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Included studies were generally assessed to be at low or unclear risk of bias for most domains; two studies were assessed as high risk for incomplete outcome data (<a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>) and selective reporting bias (<a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>). Risk of bias assessments of the included studies are summarised in <a href="#CD010612-fig-0002">Figure 2</a> and <a href="#CD010612-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010612-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010612-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010612-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010612-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010612-sec-0052"> <h4 class="title">Allocation</h4> <p>Two studies (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>) did not provide detailed information on random sequence generation and allocation concealment processes. Authors were contacted, and we were informed that random sequence generation was appropriate (computerâgenerated), and sealed opaque envelopes were used for the allocation process. We did not receive an answer about the allocation process for four studies (<a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>). </p> <p>Seven studies (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>) were assessed as being at low risk of selection bias due to appropriate random sequence generation (computerâgenerated) and for allocation concealment. </p> <p>Random sequence generation and allocation concealment were considered unclear for four studies (<a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>) as they did not provide sufficient information to enable judgment. </p> </section> <section id="CD010612-sec-0053"> <h4 class="title">Blinding</h4> <section id="CD010612-sec-0054"> <h5 class="title">Performance bias</h5> <p>Two studies were judged to be at low risk of performance bias (<a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>), and the remaining nine studies were judged to be at unclear risk of performance bias (insufficient information to enable judgment). </p> </section> <section id="CD010612-sec-0055"> <h5 class="title">Detection bias</h5> <p>All included studies were assessed at low risk of detection bias (outcome measurement was unlikely to be influenced by lack of blinding). </p> </section> </section> <section id="CD010612-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a> was assessed at high risk of attrition (data from &gt; 20% of randomised patients were not available for inclusion in the analysis). Intentionâtoâtreat analysis was performed in the other 11 studies. </p> </section> <section id="CD010612-sec-0057"> <h4 class="title">Selective reporting</h4> <p>The selective reporting bias was considered at high risk in <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a> as not all of the expected outcomes were reported. </p> </section> <section id="CD010612-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>Eight studies were judged to be at low risk of bias. Four studies received pharmaceutical industry funding (<a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>), which is a potential source of bias; however, the sponsors had no role in the design, data collection, analysis and results, review or approval of the manuscript so were judge to be at low risk of bias. The funding source was not available in the remaining four studies (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>), and these were judged to have unclear risk of bias. </p> <section id="CD010612-sec-0059"> <h5 class="title">Evaluation of publication bias</h5> <p>We constructed a funnel plot to investigate potential publication bias. Metaâanalysis of death at day 30 was analysed. We found reasonable symmetry indicating a low risk of publication bias (<a href="#CD010612-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD010612-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Early vs. late initiation, outcome: 1.1 Death." data-id="CD010612-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Early vs. late initiation, outcome: 1.1 Death.</p> </div> </div> </div> </section> </section> </section> <section id="CD010612-sec-0060"> <h3 class="title" id="CD010612-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD010612-tbl-0001"><b>Summary of findings 1</b> Early versus standard initiation of kidney replacement therapy (KRT) in patients with acute kidney injury (AKI)</a>; <a href="./full#CD010612-tbl-0002"><b>Summary of findings 2</b> Subgroup analyses: early versus standard initiation of kidney replacement therapy (KRT) in patients with acute kidney injury (AKI)</a> </p> <p>The effects of early KRT initiation versus standard for main results and the quality of the evidence are summarised inÂ <a href="./full#CD010612-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD010612-sec-0061"> <h4 class="title">Death</h4> <p>All 12 studies assessed the effect of different timing of KRT initiation on death. These studies varied in reporting timing: 90 days (<a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>); 60 days (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>); 28 days after randomisation (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>); and 14 days after coronary bypass graft surgery (<a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>). </p> <p>Compared to standard, early initiation of KRT may have little to no difference on the risk of death at day 30 (<a href="./references#CD010612-fig-0005" title="">Analysis 1.1</a>.1 (12 studies, 4826 participants): RR 0.97, 95% CI 0.87 to 1.09; IÂ² = 29%; low certainty evidence). We assessed the certainty of evidence as low due to concerns about imprecision and heterogeneity. Early start probably made little or no difference to death after 30 days postârandomisation (<a href="./references#CD010612-fig-0005" title="">Analysis 1.1</a>.2 (7 studies, 4534 participants): RR 0.99, 95% CI 0.92 to 1.07; IÂ² = 6%; moderate certainty evidence) in comparison with standard initiation. We assessed the certainty of evidence as moderate due to concerns about imprecision. The CI included both clinical benefits and harms. </p> <section id="CD010612-sec-0062"> <h5 class="title">Subgroup analysis and investigation of heterogeneity for death</h5> <p>There was evidence of moderate heterogeneity in the magnitude of the effect among the included studies that measured death at day 30 after randomisation. To explore heterogeneity among participants, we planned to perform preâspecified subgroup analyses according to the aetiology of AKI by criteria for the time of KRT initiation, modalities of KRT and severity of illness. </p> <p>The effect of AKI aetiology was considered using two subgroups: patients with AKI secondary to surgical causes and patients with AKI related to nonâsurgical causes. Compared to standard, early KRT initiation probably made little or no difference to the risk of death in patients with nonâsurgical AKI (<a href="./references#CD010612-fig-0010" title="">Analysis 2.1</a>.1 (9 studies, 4461 participants): RR 1.01, 95% CI 0.94 to 1.09; IÂ² = 0%; moderate certainty evidence) but may be reduced in surgical causes (<a href="./references#CD010612-fig-0010" title="">Analysis 2.1</a>.2 (3 studies, 365 participants): RR 0.65, 95% CI 0.31 to 1.36; IÂ² = 70%; low certainty evidence). </p> <p>Despite mild heterogeneity between groups<b>,</b> the test for subgroup differences was not statistically significant. This could be explained by the studies being underpowered to detect differences due to the small sample size of the studies with the surgicalâAKI group (Test for subgroup differences: ChiÂ² = 1.40, df = 1; P = 0.24, IÂ² = 28.3%).Â  </p> <p>The effect of different criteria used to define the time of KRT initiation was assessed using three subgroups: patients starting KRT when fulfilling criteria to stage 2 of KDIGO classification, KDIGO 3 AKI RIFLEâF stage and AKIN stage 3 criteria, and patients initiating KRT according to other criteria (biomarkers, furosemide stress test). Compared to standard KRT, early strategy may make little or no difference to death in patients initiating KRT according to KDIGO 2 (<a href="./references#CD010612-fig-0011" title="">Analysis 2.2</a>.1 (3 studies, 3258 participants): RR 0.95; 95% CI 0.78 to 1.15; IÂ² = 31%; low certainty evidence), KDIGO 3, AKI RIFLEâF stage, and AKIN stage 3 (<a href="./references#CD010612-fig-0011" title="">Analysis 2.2</a>.2 (4 studies, 1216 participants): RR 0.95; 95% CI 0.79 to 1.15; IÂ² = 31%; low certainty evidence), or patients starting KRT according to other criteria (<a href="./references#CD010612-fig-0011" title="">Analysis 2.2</a>.3 (3 studies, 218 participants): RR 1.09, 95% CI 0.86 to 1.38; IÂ² = 0%; moderate certainty evidence). There was no heterogeneity between groups (Test for subgroup differences: ChiÂ² = 0.92, df = 2; P = 0.63, IÂ² = 0%). </p> <p>The effect of KRT modalities was considered using two subgroups: patients with predominantly continuous kidney support and patients who received mixed modalities (continuous and intermittent). Compared to standard, early KRT initiation may make little or no difference to the risk of death in either the patients treated with CKRT (<a href="./references#CD010612-fig-0012" title="">Analysis 2.3</a>.1 (8 studies, 692 participants): RR 0.86, 95% CI 0.65 to 1.14; IÂ²= 48%; low certainty evidence) or patients treated with mixed modalities (<a href="./references#CD010612-fig-0012" title="">Analysis 2.3</a>.2 (4 studies, 4134 participants): RR 1.02, 95% CI 0.94 to 1.10; IÂ² = 0%; moderate certainty evidence). There was no significant heterogeneity between groups (Test for subgroup differences: ChiÂ² = 1.23; df = 1; P = 0.27, IÂ² = 18.8%). </p> <p>The effect of the severity of illness at baseline was assessed using two subgroups: patients with high and low SOFA scores (&gt; 12 and â¤ 12). Compared to standard, early KRT initiation may make little or no difference to the risk of death in patients with either a SOFA score &gt; 12 (<a href="./references#CD010612-fig-0013" title="">Analysis 2.4</a>.1 ( 3 studies, 819 participants): RR 0.95; 95% CI 0.75 to 1.20; IÂ²= 31%; low certainty evidence) or those with a SOFA score â¤ 12 (<a href="./references#CD010612-fig-0013" title="">Analysis 2.4</a>.2 ( 6 studies, 3870 participants): RR 1.02; 95% CI 0.94 to 1.10; IÂ² = 0%; moderate certainty evidence). There was no heterogeneity between groups (test for subgroup differences: ChiÂ² = 0.35; df = 1; P = 0.55; IÂ² = 0%). </p> <p>SeeÂ <a href="./full#CD010612-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD010612-sec-0063"> <h5 class="title">Sensitivity analysis</h5> <p>The sensitivity analysis was performed excluding studies by the risk of bias and size of the study. When taking risk of bias into account, we observed thatÂ <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>Â contributed to heterogeneity, and, when excluded, heterogeneity was not significant (P = 0.62; IÂ² = 0%). The reason for exclusion was incomplete outcome data (attrition bias), but the overall estimation of effect did not change, and the direction of effects remained constant. We found no changes in heterogeneity when the study with the larger sample size was excluded. </p> </section> </section> <section id="CD010612-sec-0064"> <h4 class="title">Death or nonârecovery of kidney function at 90 days</h4> <p>This composite outcome was available for six studies (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>). Compared with standard, early initiation may make little or no difference to the risk of death or nonârecovery of kidney function at 90 days (<a href="./references#CD010612-fig-0006" title="">Analysis 1.2</a>Â (6 studies, 4011 participants): RR 0.91, 95% CI 0.74 to 1.11; IÂ² = 66%; low certainty evidence). We assessed the certainty of evidence as low due to concerns about imprecision and heterogeneity. However, the CIs included clinically important benefits and harms. </p> <section id="CD010612-sec-0065"> <h5 class="title">Subgroup analysis and investigation of heterogeneity for death or nonârecovery of kidney function at 90 days </h5> <p>Compared to standard, early KRT initiation probably made little or no difference to the risk of death or nonârecovery of kidney function at 90 days with either nonâsurgical AKI (<a href="./references#CD010612-fig-0014" title="">Analysis 3.1</a>.1 (3 studies, 3646 participants): RR 1.04, 95% CI 0.97 to 1.11; IÂ² = 0%; moderate certainty evidence), or surgical causes (<a href="./references#CD010612-fig-0014" title="">Analysis 3.1</a>.2 (3 studies, 365 participants): RR 0.66, 95% CI 0.33 to 1.33; IÂ² = 70%; low certainty evidence). The test for subgroup differences was not significant (ChiÂ² = 1.60; df = 1; P = 0.21; IÂ² = 37.5%). </p> <p>Compared to standard KRT, the early strategy may make little or no difference to death or nonârecovery of kidney function at 90 days in patients initiating KRT according to KDIGO 2 (<a href="./references#CD010612-fig-0015" title="">Analysis 3.2</a>.1 (1 study, 619 participants): RR 0.95; 95% CI 0.79 to 1.11; low certainty evidence), KDIGO 3, AKI RIFLEâF stage, and AKIN stage 3 (<a href="./references#CD010612-fig-0015" title="">Analysis 3.2</a>.2 (3 studies, 3258 participants): RR 0.91; 95% CI 0.70 to 1.19; IÂ² = 70%; low certainty evidence), or patients starting KRT according to other criteria (<a href="./references#CD010612-fig-0015" title="">Analysis 3.2</a>.3 (2 studies, 134 participants): RR 0.47, 95% CI 0.07 to 3.21; IÂ² = 0%; low certainty evidence). There was no heterogeneity between groups (test for subgroup differences: ChiÂ² = 0.56; df = 2; P = 0.76; IÂ² = 0%). </p> <p>Compared to standard, early KRT initiation may make little or no difference to the risk of death or nonârecovery of kidney function at 90 days in either patients treated with CKRT (<a href="./references#CD010612-fig-0016" title="">Analysis 3.3</a>.1 (3 studies, 365 participants): RR 0.66, 95% CI 0.33 to 1.33; IÂ²= 70%; low certainty evidence) or patients treated with mixed modalities (<a href="./references#CD010612-fig-0016" title="">Analysis 3.3</a>.2 (3 studies, 3646 participants): RR 1.04, 95% CI 0.97 to 1.11; IÂ² = 0%; moderate certainty evidence). The test for subgroup differences was not significant (ChiÂ² = 1.60; df = 1; P = 0.21; IÂ² = 37.5%). </p> <p>Compared to standard, early KRT initiation may reduce the risk of death or nonârecovery of kidney function at 90 days in patients with a SOFA score &gt; 12 (<a href="./references#CD010612-fig-0017" title="">Analysis 3.4</a>.1 (2 studies, 331 participants): RR 0.77; 95% CI 0.62 to 0.97; IÂ²= 0%; low certainty evidence), but not in those with a SOFA score â¤ 12 (<a href="./references#CD010612-fig-0013" title="">Analysis 2.4</a>.2 ( 3 studies, 3652 participants): RR 1.04; 95% CI 0.97 to 1.12; IÂ² = 0%; low certainty evidence). The test for subgroup differences was significant (ChiÂ² = 6.07; df = 1; P = 0.01; IÂ² = 83.5%). </p> </section> <section id="CD010612-sec-0066"> <h5 class="title">Sensitivity analysis</h5> <p>The sensitivity analysis was performed, excluding studies by the risk of bias and studies with large sample sizes. When the analysis was developed taking risk of bias into account, we observed thatÂ <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>Â contributed to heterogeneity, and, when excluded, heterogeneity was not significant (P = 0.12; IÂ² = 46%). The reason for exclusion was study limitation (attrition bias), but the overall estimation of effect did not change, and the direction of effects remained constant. We found no changes in heterogeneity when the studies with larger sample sizes were excluded. </p> </section> </section> <section id="CD010612-sec-0067"> <h4 class="title">Recovery of kidney function</h4> <p>Ten studies reported information on recovery of kidney function (in all patients and among patientsâ survivors). Studies varied in reporting of kidney recovery timing: at 90 days after randomisation (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>), 28 days or at hospital discharge (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>;Â <a href="./references#CD010612-bbs2-0012" title="YinJ , ZhengR , LinH , ShaoJ . Influence of initiation timing of continuous renal replacement therapy on prognosis of patients with septic shock and acute kidney injury. Journal of Clinical Medicine &amp; Practice2018;22:63-6. ">Yin 2018</a>), or 14 days after coronary bypass graft surgery (<a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>). </p> <p>Compared to standard, early KRT initiation may make little or no difference to the number of patients free from KRT according to intentionâtoâtreat analysis (<a href="./references#CD010612-fig-0007" title="">Analysis 1.3</a>.1 (10 studies, 4717 participants): RR 1.07, 95% CI 0.94 to 1.22; IÂ²=55%; low certainty evidence). We assessed the certainty of evidence as low due to concerns about imprecision and heterogeneity. </p> <p>Among survivors free from KRT according to intention to treat analysis, after day 30, early initiation of KRT may make little or no difference to the recovery of kidney function compared to standard (<a href="./references#CD010612-fig-0007" title="">Analysis 1.3</a>.2 (10 studies, 2510 participants): RR 1.02, 95% CI 0.97 to 1.07; IÂ² = 69%; low certainty evidence). We assessed the certainty of evidence as low due to concerns about indirectness and heterogeneity. The CIs of both outcomes included clinical benefits and harms. </p> <section id="CD010612-sec-0068"> <h5 class="title">Subgroup analysis and investigation of heterogeneity recovery of kidney function</h5> <p>There was evidence of heterogeneity in the magnitude of the effect among the included studies that measured recovery of kidney function in all patients at different times after randomisation. To explore heterogeneity among participants, we planned to perform preâspecified subgroup analyses. Only data for AKI aetiology, parameters of early initiation and modalities were available. </p> <p>Compared to standard, early KRT initiation may make little or no difference to the recovery of kidney function in patients with AKI related to either surgical causes (<a href="./references#CD010612-fig-0018" title="">Analysis 4.1</a>.1 (3 studies, 365 participants): RR 1.36, 95% CI 0.78 to 2.38; IÂ² = 78%; low certainty evidence) or nonâsurgical AKI (<a href="./references#CD010612-fig-0018" title="">Analysis 4.1</a>.2 (7 studies, 4095 participants): RR 1.00, 95% CI 0.91 to 1.11; IÂ² = 27%; low certainty evidence). The test for subgroup differences was not significant (ChiÂ² = 1.10; df = 1; P = 0.29; IÂ² = 9.4%). </p> <p>Compared to standard, early initiation KRT may make little to no difference to the recovery of kidney function in patients initiating KRT according to KDIGO 2 criteria (<a href="./references#CD010612-fig-0019" title="">Analysis 4.2</a>.1 (3 studies, 3258 participants): RR 1.08, 95% CI 0.86 to 1.36; IÂ² = 70%; low certainty evidence), or KDIGO3, AKI RIFLEâF stage and AKIN 3 criteria (<a href="./references#CD010612-fig-0019" title="">Analysis 4.2</a>.2 (2 studies, 1107 participants): RR 1.00, 95% CI 0.88 to 1.13; IÂ² = 0%; low certainty evidence), while it may increase kidney recovery according to other criteria (<a href="./references#CD010612-fig-0019" title="">Analysis 4.2</a>.3 (3 studies, 218 participants): RR 1.55; 95% CI 0.95 to 2.53; IÂ² = 26%; low certainty evidence). The test for subgroup differences was not significant, and this could be explained by the small sample size and the small number the studies in each subgroup (test for subgroup differences: ChiÂ² = 3,07; df = 2; P = 0.22; IÂ² = 34.9%). </p> <p>Compared to standard, early KRT initiation may make little or no difference to the recovery of kidney function in patients treated with CKRT (<a href="./references#CD010612-fig-0020" title="">Analysis 4.3</a>.1 (6 studies, 583 participants): RR 1.42, 95% CI 0.99 to 2.03; IÂ² = 60%; moderate certainty evidence), and in patients treated with mixed modalities (<a href="./references#CD010612-fig-0020" title="">Analysis 4.3</a>.2 (4 studies, 4134 participants): RR 0.96, 95% CI 0.91 to 1.02; IÂ² = 0%; moderate certainty evidence). There was significant heterogeneity between the groups, and the test for subgroup differences was significant (ChiÂ² = 4.27; df =1; P = 0.04; IÂ² = 76.6%). This heterogeneity could be explained by different KRT modalities. </p> <p>SeeÂ <a href="./full#CD010612-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD010612-sec-0069"> <h5 class="title">Sensitivity analysis</h5> <p>The sensitivity analysis was performed, excluding studies at high risk of bias and studies with large sample sizes. When the analysis was developed taking risk of bias into account, we observed thatÂ <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>Â contributed to heterogeneity, and when excluded, heterogeneity was not significant (P = 0.08; IÂ² = 44%). The reason for exclusion was study limitation (attrition bias); however, the overall estimation of effect did not change, and the direction of effects remained constant. We found no changes in heterogeneity when the study with a larger sample size was excluded. </p> </section> </section> <section id="CD010612-sec-0070"> <h4 class="title">Adverse events</h4> <p>The effects of the timing of KRT initiation on adverse events were reported in seven studies (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>). </p> <p>It is uncertain whether early KRT initiation increases or reduces the number of patients who experienced any adverse events compared to standard (<a href="./references#CD010612-fig-0008" title="">Analysis 1.4</a>.1 (5 studies, 3983 participants): RR 1.23, 95% CI 0.90 to 1.68; IÂ² = 91%; very low certainty evidence). We assessed the certainty of evidence to be very low due to concerns about imprecision and very serious inconsistency. </p> <p>Early KRT initiation increased the risk of hypophosphataemia (<a href="./references#CD010612-fig-0008" title="">Analysis 1.4</a>.2 (1 study, 2927 participants): RR 1.80, 95% CI 1.33 to 2.44), hypotension (<a href="./references#CD010612-fig-0008" title="">Analysis 1.4</a>.3 (5 studies, 3864 participants): RR 1.54, 95% CI 1.29 to 1.85; IÂ² = 0%), cardiacârhythm disorder (<a href="./references#CD010612-fig-0008" title="">Analysis 1.4</a>.4 (6 studies, 4483 participants): RR 1.35, 95% CI 1.04 to 1.75; IÂ² = 16%), and infection (<a href="./references#CD010612-fig-0008" title="">Analysis 1.4</a>.5 (5 studies, 4252 participants): RR 1.33, 95% CI 1.00 to 1.77; IÂ² = 0%); with high certainty evidence. </p> <p>Early start probably reduced the risk of bleeding (<a href="./references#CD010612-fig-0008" title="">Analysis 1.4</a>.6 (6 studies, 4358 participants): RR 0.91, 95% CI 0.73 to 1.18; IÂ² = 4%; moderate certainty evidence). We assessed the certainty of evidence as moderate due to concerns about imprecision. However, it is uncertain whether early start of KRT increases or decreases the risk of thrombocytopenia (<a href="./references#CD010612-fig-0008" title="">Analysis 1.4</a>.7 (1 study, 106 participants): RR 1.03, 95% CI 0.20 to 5.35; very low certainty evidence) compared with standard initiation. We assessed the certainty of evidence as very low due to concerns about very serious imprecision and study limitation (small sample size). </p> <section id="CD010612-sec-0071"> <h5 class="title">Sensitivity analysis</h5> <p>The sensitivity analysis was performed, excluding studies at high risk of bias and studies with large sample sizes. When the analysis was developed taking the study with a larger sample size into account, we found thatÂ <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>Â contributed to heterogeneity, and when was excluded, heterogeneity decreased but remained significant (P = 0.03; IÂ² = 66%). The reason for exclusion was a large study; however, the overall estimation of effect did not change, and the direction of effects remained constant. We found no changes in heterogeneity when the study at high risk of bias was excluded. </p> </section> </section> <section id="CD010612-sec-0072"> <h4 class="title">Length of stay</h4> <p>Seven studies assessed the effect of timing on length of stay (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>). </p> <p>Early KRT initiation probably reduces the number of days in ICU (<a href="./references#CD010612-fig-0009" title="">Analysis 1.5</a>.1 (5 studies, 4240 participants): MD â1.01 days, 95% CI â1.60 to â0.42; IÂ² = 0%; moderate certainty evidence) compared to standard. We assessed the certainty of evidence as moderate due to concerns about indirectness. </p> <p>Likewise, early KRT probably reduces the number of days in hospital compared with standard KRT initiation (<a href="./references#CD010612-fig-0009" title="">Analysis 1.5</a>.2 (7 studies,4589 participants): MD â2.45 days, 95% CI â4.75 to â0.14; IÂ² = 10%; moderate certainty evidence). We assessed the certainty of evidence as moderate due to concerns about indirectness. </p> </section> <section id="CD010612-sec-0073"> <h4 class="title">Cost</h4> <p>This outcome was not reported by any of the included studies. We did not identify highâquality nonâRCTs reporting safety and cost outcomes. </p> </section> <section id="CD010612-sec-0074"> <h4 class="title">Metaâregression</h4> <p>Considering that we found statistical and clinical heterogeneity on main outcomes, we performed nonâprespecified metaâregression using STATA 14.1 to explore the effect of coâvariables for which we had data. </p> <p> <ol id="CD010612-list-0014"> <li> <p><b>Type of participants</b> (patients with AKI related to nonâsurgical causes or patients with AKI related to surgical causes) </p> </li> <li> <p><b>Fluid overload</b> (FO) after randomisation, based on the three categories (FO â¤ 3 L, FO = 3 to &lt; 6 L and FO â¥ 6 L) </p> </li> <li> <p><b>Absolute difference</b> in fluid overload after randomisation between standard group minus interventions group </p> </li> <li> <p><b>KRT modality</b> (continuous and intermittent + continuous) </p> </li> <li> <p><b>Hypotension</b>: difference between the percentage of patients with hypotension in the early group minus the standard group. </p> </li> </ol> </p> <p>We performed metaâregression on the primary and secondary outcomes with results of six to nine studies: death at day 30, kidney recovery function in all patients, and hospital length of stay. We did not find significant results explaining sources of heterogeneity using this analysis. None of the explanatory variables analysed influenced the size of the intervention or affected the outcomes evaluated. Details on the definitions of variables, data set, and outcomes measures are available inÂ <a href="./appendices#CD010612-sec-0089">Appendix 3</a> </p> <p>In order to show some aspects of the heterogeneous results, we present crude results of the investigated outcomes for the six and nine included studies. The files of the table were ordered from top to bottom by type of patient, fluid overload, the difference in the amount of fluid overload after randomisation, hypotension, and KRT modality between groups (SeeÂ <a href="./appendices#CD010612-sec-0090">Appendix 4</a>;Â <a href="./appendices#CD010612-sec-0091">Appendix 5</a>;Â <a href="./appendices#CD010612-sec-0092">Appendix 6</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010612-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010612-sec-0075"></div> <section id="CD010612-sec-0076"> <h3 class="title" id="CD010612-sec-0076">Summary of main results</h3> <p>Our systematic review and subsequent metaâanalysis examined the effect of different timing of initiation of KRT on death, kidney recovery function, length of stay, and adverse events among 4880 randomised critically ill patients with AKI. Most of the included studies were assessed as having a low or unclear risk of bias for all domains. Two studies were assessed as having a high risk bias, one for incomplete outcome data (attrition bias) and the other for selective reporting (reporting bias). </p> <p>Within the time of KRT initiation assessed, earlier start may have no beneficial effect on death or recovery of kidney function (in all patients) compared to standard strategy. </p> <p>Within the time of KRT initiation assessed, earlier start may have little to no difference on death at day 30<b>.</b> The overall estimated effects on risk of death showed clinically small benefits (decreased death by 3%), but the CIs were sufficiently wide to include benefits and harm (imprecision), with a low level of heterogeneity (IÂ² = 29%; inconsistency). The 3% relative risk reduction (RRR) in death at day 30 in the early KRT group is related to a reduction in absolute risk observed in only 12 of 1000 patients (50 less or 35 more than those treated with late KRT), thus assuming little to no effect on death. </p> <p>Early strategy probably makes little to no difference on death after day 30, with imprecision and without inconsistency (IÂ² = 6%). </p> <p>Early strategy may make little or no difference to the risk of death or nonârecovery of kidney function at day 90. The overall estimated effects on risk of death showed clinical benefits (decreased death by 9%), but the CIs were sufficiently wide to include benefits and harm (imprecision), with a moderate level of heterogeneity (IÂ² = 66%; inconsistency). However, when we removedÂ <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>, the IÂ² is reduced to 46%, and the imprecision was also reduced. There are no significant differences between the groups (subgroup test P = 0.12, IÂ² = 43%). The RR went from 0.91 (95% CI 0.74 to 1.11) to 0.96 (95% CI 0.83 to 1.10), which is compatible with little to no difference in death or nonârecovery kidney function at day 90. This study was assessed as having a high risk of bias by incomplete outcome data (attrition bias) (See Sensitivity analysis andÂ <a href="#CD010612-sec-0077">Overall completeness and applicability of evidence</a>). </p> <p>Early start may make little or no difference to the number of patients who recovered kidney function. CIs included damage (imprecision), with a moderate level of heterogeneity (IÂ² = 55%; inconsistency). There was little to no difference in kidney recovery among survivors between interventions. However, reporting kidney recovery among survivors alone does not preserve the previously achieved randomisation. Therefore, the interpretation of this result may be misleading, given death is a competing endpoint for recovery of kidney function in patients with a high shortâterm risk of death (indirectness). However, when we removed three studies (<a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>), the IÂ² was reduced to 25%. The RR went from 1.07 (95% CI 0.94 to 1.22) to RR 1.00 (95% CI 0.92 to 1.09), which is compatible with little to no difference in the recovery of kidney function. These studies were sources of heterogeneity probably due to selection bias (<a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>), attrition bias (<a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>) and no blinding (<a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>), thus limiting the internal validity.Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>Â andÂ <a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>Â used AKIâbiomarker (high level of urinary or serum NGAL) as criteria for early KRT initiation. </p> <p>It is uncertain whether early KRT initiation increases or reduces the number of patients who experienced any adverse events compared to standard, with a substantial level of heterogeneity (IÂ² = 91%; inconsistency). Nevertheless, the early strategy did increase the risk of hypophosphataemia, hypotension, cardiac rhythm disorder and infections, although it had uncertain effects on thrombocytopenia and the risk of bleeding when compared to standard initiation. </p> <p>Early start probably reduces the length of ICU and hospital stay (number of days). The magnitude of the possible benefit was clinically relevant (â1.01 days to â2.45 days, respectively). These results should be interpreted with caution owing to the indirectness observed (in this population, death is a competing endpoint for the length of stay). </p> <p>With a focus on the effect size of the central estimation (magnitude or importance), we observed that early initiation may make little to no difference to death, may improve the recovery of kidney function, probably reduces the length of ICU and hospital stay, while it increased the risk of adverse events. However, all results (except any adverse events and length of stay) were imprecise because the CIs crossed both the important effect threshold and the no difference threshold. </p> <p>An important limitation of this systematic review was the low to moderate heterogeneity found in the main results, as death at day 30 (IÂ² = 29%), death or nonârecovery of kidney function at 90 days (IÂ² = 66%), and on recovery of kidney function in all patients (IÂ² = 55%). There was no heterogeneity identified for the length of stay, and adverse events (hypophosphataemia, hypotension, cardiac rhythm disorder and infections), except for the number of patients with any adverse event (IÂ² = 91%). </p> <p>We explored this heterogeneity by prespecified subgroup analyses: aetiology of AKI, according to criteria used to define the timing of KRT initiation, modalities of KRT, and the severity of illness at baseline. The subgroup modality of KRT initiation was identified as a source of heterogeneity in the size of the effect observed in the recovery of kidney function (test for subgroup differences: ChiÂ² = 4.27; P = 0.04; IÂ² = 76.6%). These results should be interpreted with caution as only five small studies contributed to these data. Notably, several studies reported that there were more hypotension events with intermittent haemodialysis, which was more likely to result in haemodynamic instability than CKRT, with a lower likelihood of kidney recovery after AKI. </p> <p>In the subgroup of aetiology of AKI, we observed a reduction in death (35%) in patients with surgeryâacquired compared to those patients with nonâsurgeryâacquired AKI (increased risk 1%). Despite some heterogeneity (IÂ² = 28.3%) between groups, the test for subgroup difference was not statistically significant. This could be explained by the studies being underpowered to detect differences due to the small sample size of the studies with the surgicalâAKI group. However, if we removeÂ <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>, the IÂ² is reduced to 13%, and the imprecision is also reduced. The RR goes from 0.65 (95% CI 0.31 to 1.36) to 0.84 (95% CI 0.59 to 1.20). The effect size is lower but still clinically relevant. This study was assessed as having a high risk of bias by incomplete outcome data (attrition bias) (SeeÂ <a href="#CD010612-sec-0077">Overall completeness and applicability of evidence</a>). </p> <p>In the subgroup of KRT modalities reduction in death (14%) was observed in patients with CKRT compared to those patients with mixed KRT modality (increased risk 2%). Without heterogeneity (IÂ² = 0%) between groups, the test for subgroup difference was not statistically significant. However, when we removedÂ <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>, the IÂ² is reduced from 48% to 7%, and the imprecision was also reduced. The RR goes from 0.86 (95% CI 0.65 to 1.14) to 0.93 (95% CI 0.77 to 1.13) (SeeÂ <a href="#CD010612-sec-0077">Overall completeness and applicability of evidence</a>). </p> <p>In the subgroup of aetiology of AKI, we observed an increase in kidney recovery rate (36%) in patients with surgeryâacquired compared to those patients with nonâsurgeryâacquired AKI. Without (IÂ² = 9.4%) between groups, the test for subgroup difference was not statistically significant. This could be explained by the underpowered to detect differences due to the small sample size of the studies with the surgicalâAKI group. However, if we removeÂ <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>, the IÂ² is reduced to 0%, and the imprecision was also reduced. The RR goes from 1.36 (95% CI 0.78 to 2.38) to 1.12 (95% CI 0.72 to 1.74). The effect size is lower but still clinically relevant. This study was assessed as having a high risk of bias by incomplete outcome data (attrition bias) (SeeÂ <a href="#CD010612-sec-0077">Overall completeness and applicability of evidence</a>). </p> <p>For the death or nonârecovery of kidney function at 90 days, the subgroups aetiology (surgical and nonâsurgical), initiation criteria KDIGO 2, KDIGO 3, AKI RIFLEâF stage, and AKIN stage 3, or other criteria) and modality (CKRT or mixed KRT) made little or no difference to this outcome. Early initiation may reduce the risk of death or nonârecovery of kidney function at 90 days in patients with a SOFA score &gt; 12 but not in those with a SOFA score â¤ 12. </p> <p>RCTs focusing on the timing of KRT initiation for paediatric AKI patients were not available. </p> </section> <section id="CD010612-sec-0077"> <h3 class="title" id="CD010612-sec-0077">Overall completeness and applicability of evidence</h3> <p>Although the analyses included data obtained from a comprehensive and rigorous search, we identified gaps in several areas. The majority of participants in the included studies were adults, limiting the applicability of our finding to children. In general, the incidence of AKI secondary to sepsis in ICU is high; however, in three studies, it was observed that the majority of patients had postâsurgical AKI, and relatively few had sepsis or preâexisting chronic kidney disease (CKD), limiting the applicability of our results to general ICU population. </p> <p>Six studies were singleâcentre, and all were unblinded, limiting the external and internal validity of the results, respectively. </p> <p>Data on the number of patients with any adverse events were limited and only provided by five of the 12 studies in our review. </p> <p>Few studies reported data for KRT dosage and volume overload; we are aware that it is an important issue to consider in relation to death in critically ill patients with AKI. </p> <p>Most of the studies did not report data on death in patients with preâexisting CKD.</p> <p>There were large variations in the definition of the timing of KRT initiation among included studies. Heterogeneous indicators such as different serum urea or SCr levels, urine output, time from randomisation and time to fulfil KDIGO AKI stage, biochemical markers and furosemide test are widely used to measure the timing of KRT; however, this approach provides an incomplete assessment of optimal timing of KRT initiation in this population and limits the applicability of our results. </p> <p>It is important to highlight the absence of data related to the characteristics and evolution of patients randomised to the standard or late arm who did not receive dialysis treatment. These data would allow us to develop a propensityâbased analysis of patients in the accelerated group and among those who did not receive KRT in the standard/delayed strategy in order to define where these patients could have had a better outcome. </p> <p>We were unable to address all of the objectives of this review due to the lack of data in the included studies. Also, we did not have individual patient data for the different subgroups of the modality of KRT and aetiology of AKI, being a limitation of our review </p> <p>The RCTs included as well as recent research byÂ <a href="./references#CD010612-bbs2-0116" title="GaudryS , HajageD , BenichouN , ChaibiK , BarbarS , ZarbockA , et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet2020;395(10235):1506-15. [MEDLINE: 32334654]">Gaudry 2020</a>, provided new knowledge and tools, such as the use of furosemide stress test or emerging biomarkers of persistent severe AKI and clinical judgment, that will help us define the optimal KRT initiation time in order to recognize when early KRT initiation may be essential for better outcomes or unnecessary due to potential harms for AKIâpatients in ICU. </p> <p>We included only RCTs with the purpose of reducing bias.</p> </section> <section id="CD010612-sec-0078"> <h3 class="title" id="CD010612-sec-0078">Quality of the evidence</h3> <p>We conducted this review according to the process described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010612-bbs2-0122" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). Our review was based on evidence from 12 RCTs (4880 randomised participants) that compared different timing of KRT initiation in critically ill patients with AKI. The certainty evidence for our main outcomes was drawn from studies assessed at low risk of bias for random sequence generation and allocation concealment processes, incomplete outcomes data, intention to treat analysis, selective outcomes reporting, performance and detection bias and other sources of bias; as well as unclear risk for detection bias. Two studies were at high risk of bias by incomplete outcome data (attrition bias) and selective reporting (reporting bias). Three small studies had an unclear risk of selection bias. </p> <p>Data comparing the effect of early KRT initiation against standard initiation on death at day 30 or after were obtained from 12 and seven wellâconducted RCTs, respectively, but we downgraded the certainty of evidence to low, mainly due to inconsistency (IÂ² = 29%) and imprecision (CIs included a range of plausible value with clinically important benefits, but also harm), and rated it as moderate by imprecision for death after 30 days. Similarly, we downgraded the certainty of evidence to low for recovery of kidney function in all patients due to imprecision and inconsistency (IÂ² = 55%) and rated as low data obtained for recovery of kidney function among survivors by inconsistency (IÂ² = 69%) and indirectness (the recovery of kidney function in this highârisk group is affected when the risk of death is taken into account). </p> <p>Data used to assess the impact of early versus standard initiation of KRT on adverse events were obtained from eight wellâconducted RCTs, providing treatment effects with clinically important harms for hypophosphataemia, hypotension, cardiacârhythm disorder and infections. We rated this as highâcertainty evidence. Six studies reported the number of patients with bleeding; and were rated as moderate by imprecision. One study provided data on the number of patients with thrombocytopenia; we downgraded the certainty of evidence to very low due to serious imprecision and study limitation (one study with a small sample size). In the same way, we downgraded the certainty of evidence as very low owing to imprecision and substantial inconsistency (I Â²= 91%) observed in the number of patients with some kind of adverse event (data provided by five RCTs). </p> <p>Length of ICU and hospital stay was reported by five and seven RCTs, respectively; we downgraded the certainty of evidence to moderate due to indirectness, as death is a competing endpoint for the length of stay in this population. </p> </section> <section id="CD010612-sec-0079"> <h3 class="title" id="CD010612-sec-0079">Potential biases in the review process</h3> <p>While this review was conducted according to rigorous methods developed by the Cochrane Collaboration, some bias may be present in the review process. We searched for all relevant studies using sensitive and validated strategies in major medical databases and grey literature sources. However, it is possible that some studies (such as unpublished data and studies with negative or no effects) were not identified. An analysis of evidence to assess the risk of publication bias was not possible for all outcomes due to the number of studies available in each metaâanalysis (<a href="#CD010612-fig-0004">Figure 4</a>). </p> <p>Several subgroup analyses were planned to explore potential sources of heterogeneity in our review; however, a lack of data prevented us from performing these analyses. </p> </section> <section id="CD010612-sec-0080"> <h3 class="title" id="CD010612-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>Our systematic review, in keeping with previous metaâanalyses on timing in KRT (<a href="./references#CD010612-bbs2-0116" title="GaudryS , HajageD , BenichouN , ChaibiK , BarbarS , ZarbockA , et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet2020;395(10235):1506-15. [MEDLINE: 32334654]">Gaudry 2020</a>;Â <a href="./references#CD010612-bbs2-0126" title="LiX , Liu Ch, MaoZ , LiQ , ZhouF . Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Critical Care2021;25(1):15. [MEDLINE: 3407756]">Li 2021</a>;Â <a href="./references#CD010612-bbs2-0132" title="NaorungrojT , NetoAS , YanaseF , EastwoodG , WaldR , BagshawS , et al. Time to initiation of renal replacement therapy among critically ill patients with acute kidney injury: a current systematic review and meta-analysis. Critical Care Medicine2021;49(8):e781-92. [MEDLINE: 3386155]">Naorungroj 2021</a>;Â <a href="./references#CD010612-bbs2-0136" title="PanH , ChenY , TsaiI , ShiaoC , HuangT , ChanCK , et al. Accelerated versus standard initiation of renal replacement therapy for critically ill patients with acute kidney injury: a systematic review and meta-analysis of RCT studies. Critical Care2021;25(1):5. [MEDLINE: 33402204]">Pan 2021</a>), found that earlier KRT initiation may have no beneficial effect on death in critically ill patients with AKI compared with later strategy. These results were not consistent with two other systematic reviews that included randomised and observational studies (<a href="./references#CD010612-bbs2-0140" title="SeabraVF , BalkEM , LiangosO , SosaAM , CendorogloM , JaberBL . Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. American Journal of Kidney Diseases2008;52(2):272-84. [MEDLINE: 18562058]">Seabra 2008</a>;Â <a href="./references#CD010612-bbs2-0148" title="WierstraB , KadriS , AlomarS , BurbanoX , BarrisfordG , KaoR . The impact of âearlyâ versus âlateâ initiation of renal replacement therapy in critical care patients with acute kidney injury: a systematic review and evidence synthesis. Critical Care (London, England)2016;20(1):122. [MEDLINE: 27149861]">Wierstra 2016</a>) and other metaâanalyses based only on RCTs (<a href="./references#CD010612-bbs2-0129" title="MavrakanasTA , Aurian-BlajeniDE , CharytanDM . Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a meta-analysis of randomised clinical trials. Swiss Medical Weekly2017;147:w14507. [MEDLINE: 29039628]">Mavrakanas 2017</a>;Â <a href="./references#CD010612-bbs2-0147" title="WangC , LvLS , HuangH , GuanJ , Ye Z, LiS , et al. Initiation time of renal replacement therapy on patients with acute kidney injury: a systematic review and meta-analysis of 8179 participants. Nephrology2017;22(1):7-18. [MEDLINE: 27505178]">Wang 2017</a>;Â <a href="./references#CD010612-bbs2-0149" title="XuY , GaoJ , ZhengX , ZhongB , NaY , WeiJ . Timing of initiation of renal replacement therapy for acute kidney injury: a systematic review and meta-analysis of randomised-controlled trial. Clinical &amp; Experimental Nephrology2017;21(4):552â62. [MEDLINE: 27485542]">Xu 2017</a>) </p> <p>The hypothesis that critical AKI patients, especially those with acidaemia, fluid overload, or systemic inflammation, could benefit from early KRT was proposed by several researchers. Our review has found that early strategy may have little to no difference on death at day 30. This result is consistent with five multicentre RCTs (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>) but does not agree with those reported in three individual RCTs (<a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0010" title="TangX . Timing of initiation of continuous renal replacement therapy for sepsis patients with acute kidney injury. Journal of Internal Intensive Medicine2016;2:137-9. ">Tang 2016</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>) </p> <p>It is important to note that differences in death betweenÂ <a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>Â andÂ <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>Â were observed (41.6% versus 30.4% at day 30, respectively). These differences may be due to several factors, which include: different severity levels and aetiology of AKI, e.g. prevalence of patients with AKI related to surgical cause in theÂ <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>Â or septic AKIâpatients was more frequent inÂ <a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>; both aetiologies have different pathophysiology and prognosis), and variable criteria for defining early KRT initiation (KDIGO AKI stage 3 forÂ <a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>Â and KDIGO AKI stage 2 forÂ <a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>). </p> <p>Other timing criteria were observed: serum and urinary biomarkers (<a href="./references#CD010612-bbs2-0003" title="SrisawatN , LaoveeravatP , LimphunudomP , LumlertgulN , PeerapornratanaS , TiranathanagulK , et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. Journal of Critical Care2018;43:36-41. [MEDLINE: 28843662]SrisawatN , TiranathanagulK , SusantitaphongP , PraditpornsilpaK , Eiam-OngS , TungsangaK . The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT Trial): a randomized controlled trial [abstract no: TH-OR029]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):7A. ">EARLYRRT 2018</a>;Â <a href="./references#CD010612-bbs2-0011" title="XiaY , ShiH , WuW , WangX . Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. Medical Journal of Chinese People's Liberation Army2019;44(7):605-10. [EMBASE: 2002347310]">Xia 2019</a>), or furosemide test (<a href="./references#CD010612-bbs2-0005" title="LumlertgulN , PeerapornratanaS , SurasitK , TrakarnvanichT , PongsittisakW , TankeeP , et al. The effect of early initiation of renal replacement therapy guided by furosemide stress test on clinical outcomes: a multicenter randomised controlled trial (FST trial) [abstract no: TH-OR099]. Journal of the American Society of Nephrology2017;2(Abstract Suppl):26. [EMBASE: 633701161]LumlertgulN , PeerapornratanaS , TrakarnvanichT , PongsittisakW , SurasitK , ChuasuwanA , et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care (London, England)2018;22(1):101. [MEDLINE: 29673370]">FST 2018</a>), and the equipoise judgment of clinicians for inclusion in the standard arm (<a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>) (SeeÂ <a href="#CD010612-sec-0077">Overall completeness and applicability of evidence</a>). </p> <p>There has been increased interest in the recovery of kidney function. Indeed, lack of recovery of kidney function implies the need for longâterm dialysis associated with low quality of life and high health costs. Our review has found that early strategy may have a slightly beneficial effect on the recovery of kidney function in all patients. This finding is consistent with two individual RCTs (<a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0009" title="SugaharaS , SuzukiH . Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodialysis International2004;8(4):320-5. [MEDLINE: 19379436]">Sugahara 2004</a>) (with high kidney recovery rate), and does not agree with the other three multicentre RCTs (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>). Differences in the recovery of kidney function between studies may be due to the same factors mentioned above. However, in patients with a high shortâterm death risk, the interpretation of this result may be misleading, given that death is a competing endpoint for recovery of kidney function (<a href="./references#CD010612-bbs2-0135" title="PalevskyPM , BaldwinI , DavenportA , GoldsteinS , PaganiniE . Renal replacement therapy and the kidney: minimizing the impact of renal replacement therapy on recovery of acute renal failure. Current Opinion in Critical Care2005;11(6):548-54. [MEDLINE: 16292058]">Palevsky 2005</a>). </p> <p>Patients with AKI experience longer ICU and hospital stays. In our review, the earlier strategy probably reduce ICU and hospital length of stay; this result is consistent with individual RCTs and metaâanalyses (<a href="./references#CD010612-bbs2-0004" title="MeerschM , KullmarM , SchmidtC , GerssJ , WeinhageT , MargrafA , et al. Long-term clinical outcomes after early initiation of RRT in critically ill patients with AKI. Journal of the American Society of Nephrology2018;29(3):1011-9. [MEDLINE: 29196304]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17(1):260; PMID: 27216334]. Trials [Electronic Resource]2016;17(1):148. [MEDLINE: 26993261]ZarbockA , GersJ , Van AkenH , BoantaA , KellumJA , MeerschM . Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial [Erratum for Trials. 2016 Mar 18;17(1):148. doi: 10.1186/s13063-016-1249-9.; PMID: 26993261]. Trials [Electronic Resource]2016;17(1):260. [MEDLINE: 27216334]ZarbockA , KellumJA , SchmidtC , Van AkenH , WempeC , PavenstadtH , et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA2016;315(20):2190-9. [MEDLINE: 27209269]">ELAIN 2016</a>;Â <a href="./references#CD010612-bbs2-0008" title="SmithOM , WaldR , AdhikariNK , PopeK , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:320. [MEDLINE: 24093950]WaldR , AdhikariN , PopeKL , SmithOM , WeirMA , BagshawSM . Standard versus accelerated initiation of renal replacement therapy in acute kidney injury [abstract no: SA-PO1095]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B4. WaldR , AdhikariNK , SmithOM , WeirMA , PopeK , CohenA , et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney International2015;88(4):897-904. [MEDLINE: 26154928]">STARRTâAKI Pilot 2013</a>;Â <a href="./references#CD010612-bbs2-0132" title="NaorungrojT , NetoAS , YanaseF , EastwoodG , WaldR , BagshawS , et al. Time to initiation of renal replacement therapy among critically ill patients with acute kidney injury: a current systematic review and meta-analysis. Critical Care Medicine2021;49(8):e781-92. [MEDLINE: 3386155]">Naorungroj 2021</a>) and does not agree with other RCT reports (<a href="./references#CD010612-bbs2-0001" title="ChaibiK , EhoomanF , HajageD , SchortgenF , Martin-LefevreL , VerneyC , et al. Initiation strategies for renal replacement therapy for acute kidney injury and long-term survival-a follow-up from the AKIKI randomised controlled trial [abstract no: CO-04]. Annals of Intensive Care2019;9(Suppl 1):5. [EMBASE: 630113646]GaudryS , BenichouN , LebbahS , HajageD , Martin-LefÃ¨vreL , PonsB , et al. Vascular access for renal replacement therapy among 459 patients A patients a pragmatic analysis of the randomised AKIKI trial [abstract no: F-87]. Annals of Intensive Care2018;8(Suppl 1):70. [EMBASE: 620836765]GaudryS , HajageD , SchortgenF , Martin-LefevreL , PonsB , BouletE , et al. Initiation strategies for renal-replacement therapy in the intensive care unit. New England Journal of Medicine2016;375(2):122-33. [MEDLINE: 27181456]GaudryS , HajageD , SchortgenF , Martin-LefevreL , RicardJ , DreyfussD . Comparison of two strategies for initiating renal replacement therapy in the ICU: Study protocol plan for a multicenter, randomised, controlled trial from the AKIKI Research Group [abstract no: P299]. Critical Care (London, England)2015;19(Suppl 1):S106. [EMBASE: 71938703]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomised controlled trial (AKIKI). Trials [Electronic Resource]2015;16(1):170. [MEDLINE: 25902813]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , PonsB , et al. Effect of renal replacement therapy strategies in septic-shock patients with severe acute kidney injury: a post hoc analysis of a randomised controlled trial [abstract]. Annals of Intensive Care2017;7(1 Suppl 1):5. [EMBASE: 614625655]GaudryS , HajageD , SchortgenF , Martin-LefevreL , TubachF , RicardJ , et al. Initiation strategies for renal replacement therapy according to severity and septic shock: A post-hoc analysis of the AKIKI trial [abstract no: A7136]. American Journal of Respiratory and Critical Care Medicine2017;195. [EMBASE: 617710393]GaudryS , HajageD , SchortgenF , Martin-LefevreL , VerneyC , PonsB , et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomised clinical trial. American Journal of Respiratory &amp; Critical Care Medicine2018;198(1):58-66. [MEDLINE: 29351007]GaudryS , VerneyC , HajageD , Martin-LefÃ¨vreL , PonsB , BouletE , et al. Renal replacement therapy initiation strategies for critically ill patients with acute on chronic renal failure: a post hoc analysis of the AKIKI trial [abstract no: CO-76]. Annals of Intensive Care2018;8(1 Suppl 1):27. [EMBASE: 620836751]GaudryS , VerneyC , HajageD , RicardJD , DreyfussD . Hypothesis: early renal replacement therapy increases mortality in critically ill patients with acute on chronic renal failure. A post hoc analysis of the AKIKI trial. Intensive Care Medicine2018;44(8):1360-1. [MEDLINE: 29754309]ScartonM , OppenheimerA , ChaibiK , DreyfussD , GaudryS . Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Critical Care (London, England)2019;23(1):148. [MEDLINE: 31036047]">AKIKI 2015</a>;Â <a href="./references#CD010612-bbs2-0006" title="BarbarSD , BinquetC , MonchiM , BruyereR , QuenotJP . Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomised controlled trial. Trials2014;15:270. [MEDLINE: 24998258]BarbarSD , Clere-JehlR , BourredjemA , HernuR , MontiniF , BruyereR , et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. New England Journal of Medicine2018;379(15):1431-42. [MEDLINE: 30304656]">IDEALâICU 2014</a>) and metaâanalyses (<a href="./references#CD010612-bbs2-0116" title="GaudryS , HajageD , BenichouN , ChaibiK , BarbarS , ZarbockA , et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet2020;395(10235):1506-15. [MEDLINE: 32334654]">Gaudry 2020</a>;Â <a href="./references#CD010612-bbs2-0126" title="LiX , Liu Ch, MaoZ , LiQ , ZhouF . Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Critical Care2021;25(1):15. [MEDLINE: 3407756]">Li 2021</a>). However, the length of stay in this highârisk population may be affected when death is taken into account. </p> <p>There was an increased risk in the number of patients who had specific adverse events with early initiation of KRT compared with standard. Our results were consistent with other RCTs (<a href="./references#CD010612-bbs2-0002" title="BoumanCS , Oudemans-Van StraatenHM , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high-volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomised trial. Critical Care Medicine2002;30(10):2205-11. [MEDLINE: 12394945]">Bouman 2002</a>;Â <a href="./references#CD010612-bbs2-0007" title="BouchardJ , CutterG , MehtaR . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1796. [MEDLINE: 33113305]LuijnenburgTW , PetjakM , dePontAJ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113306]STARRT-AKI Investigators, Canadian Critical Care Trials Group, New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Irish Critical Care Trials Group, BagshawSM , et al. Timing of Initiation of renal-replacement therapy in acute kidney injury [Erratum in: N Engl J Med. 2020 Jul 15; PMID: 32672427]. New England Journal of Medicine2020;383(3):240-51. [MEDLINE: 32668114]STARRT-AKI Investigators. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Critical Care &amp; Resuscitation2019;21(3):162-70. [MEDLINE: 31462203]START-AKI Investigators. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: study protocol for a multi-national, multi-center, randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2019;6. [MEDLINE: 31218013]SuY , TuGW , LuoZ . Timing of initiation of renal-replacement therapy in acute kidney injury. New England Journal of Medicine2020;383(18):1797. [MEDLINE: 33113307]">STARRTâAKI 2019</a>) and metaâanalyses (<a href="./references#CD010612-bbs2-0126" title="LiX , Liu Ch, MaoZ , LiQ , ZhouF . Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Critical Care2021;25(1):15. [MEDLINE: 3407756]">Li 2021</a>;Â <a href="./references#CD010612-bbs2-0132" title="NaorungrojT , NetoAS , YanaseF , EastwoodG , WaldR , BagshawS , et al. Time to initiation of renal replacement therapy among critically ill patients with acute kidney injury: a current systematic review and meta-analysis. Critical Care Medicine2021;49(8):e781-92. [MEDLINE: 3386155]">Naorungroj 2021</a>). </p> <p>Our review has an important limitation due to the heterogeneity observed in the main outcomes. Only in kidney recovery did we find an association between the estimated effect and KRT modality in agreement with a recent metaâanalysis (<a href="./references#CD010612-bbs2-0136" title="PanH , ChenY , TsaiI , ShiaoC , HuangT , ChanCK , et al. Accelerated versus standard initiation of renal replacement therapy for critically ill patients with acute kidney injury: a systematic review and meta-analysis of RCT studies. Critical Care2021;25(1):5. [MEDLINE: 33402204]">Pan 2021</a>). We were unable to address all of the preâspecified subgroup analyses of this review due to the lack of data in the included studies. </p> <p>Our review includes studies of different countries (Europe, North America and Asia) which increase the applicability of these results. </p> <p>Previous reviews explored the effect of time to KRT initiation in patients with AKI; however, these reviews included studies that we excluded from our review due to the following factors: different inclusion criteria applied, e.g. hospitalised patients were not in an ICU setting (<a href="./references#CD010612-bbs2-0074" title="PursnaniML , HazraDK , SinghB , PandeyDN . Early haemodialysis in acute tubular necrosis. Journal of the Association of Physicians of India1997;45(11):850-2. [MEDLINE: 11229183]">Pursnani 1997</a>) or did not require AKI for enrolment in the early arm (<a href="./references#CD010612-bbs2-0034" title="DurmazI , YagdiT , CalkavurT , MahmudovR , ApaydinAZ , PosaciogluH , et al. Prophylactic dialysis in patients with renal dysfunction undergoing on-pump coronary artery bypass surgery. Annals of Thoracic Surgery2003;75(3):859-64. [MEDLINE: 12645707]">Durmaz 2003</a>;Â <a href="./references#CD010612-bbs2-0044" title="CombesA , BrechotN , AmourJ , CozicN , LebretonG , GuidonC , et al. Early high-volume hemofiltration versus standard care for post-cardiac surgery shock. the HEROICS study. American Journal of Respiratory &amp; Critical Care Medicine2015;192(10):1179-90. [MEDLINE: 26167637]">HEROICS 2015</a>;Â <a href="./references#CD010612-bbs2-0046" title="JamaleTE , HaseNK , KulkarniM , PradeepKJ , KeskarV , JawaleS , et al. Earlier-start versus usual-start dialysis in patients with community-acquired acute kidney injury: a randomized controlled trial. American Journal of Kidney Diseases2013;62(6):1116-21. [MEDLINE: 23932821]">Jamale 2013</a>;Â <a href="./references#CD010612-bbs2-0055" title="KooJ , YoonJ , OhJ , LeeY , KimS , SeoJ , et al. Prospective evaluation of early continuous venovenous hemofiltration (CVVH) on the outcome in patients with severe sepsis or septic shock [abstract no: F-FC062]. Journal of the American Society of Nephrology2006;17(Abstract):50A. ">Koo 2006</a>) and differences in the methodological studies design (cohort studies). Although the abundance of cohort studies provided more power (increases the sample size) to find significant clinical differences between both treatments, these studies have important limitations: patients between intervention groups were different (e.g. patients assigned to late arm treatment might have died before initiating the therapy, while others who lived enough to be assigned to the late group might have been less sick or with a high likelihood of recovering kidney function without KRT). A relevant point worth considering is that patients do not have the same opportunity to receive early or standard treatment (allocation or selection bias). Consequently, to minimise the risk of bias in our review, we included only RCTs for our main outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010612-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow chart showing number of reports retrieved by database searching and the number of studies included in this review" data-id="CD010612-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart showing number of reports retrieved by database searching and the number of studies included in this review </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010612-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010612-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Early vs. late initiation, outcome: 1.1 Death." data-id="CD010612-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Early vs. late initiation, outcome: 1.1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early versus standard initiation, Outcome 1: Death" data-id="CD010612-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Early versus standard initiation, Outcome 1: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early versus standard initiation, Outcome 2: Death or nonârecovery kidney function at day 90" data-id="CD010612-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Early versus standard initiation, Outcome 2: Death or nonârecovery kidney function at day 90 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early versus standard initiation, Outcome 3: Recovery of kidney function" data-id="CD010612-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Early versus standard initiation, Outcome 3: Recovery of kidney function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early versus standard initiation, Outcome 4: Adverse events" data-id="CD010612-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Early versus standard initiation, Outcome 4: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early versus standard initiation, Outcome 5: Length of stay" data-id="CD010612-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Early versus standard initiation, Outcome 5: Length of stay</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: death, Outcome 1: Death by AKI aetiology" data-id="CD010612-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: death, Outcome 1: Death by AKI aetiology</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: death, Outcome 2: Death by KRT initiation" data-id="CD010612-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: death, Outcome 2: Death by KRT initiation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: death, Outcome 3: Death by KRT modality" data-id="CD010612-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: death, Outcome 3: Death by KRT modality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: death, Outcome 4: Death by illness severity score" data-id="CD010612-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: death, Outcome 4: Death by illness severity score</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: death or nonârecovery of kidney function at day 90, Outcome 1: AKI aetiology" data-id="CD010612-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: death or nonârecovery of kidney function at day 90, Outcome 1: AKI aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: death or nonârecovery of kidney function at day 90, Outcome 2: AKI criteria" data-id="CD010612-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: death or nonârecovery of kidney function at day 90, Outcome 2: AKI criteria </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: death or nonârecovery of kidney function at day 90, Outcome 3: KRT modality" data-id="CD010612-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: death or nonârecovery of kidney function at day 90, Outcome 3: KRT modality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: death or nonârecovery of kidney function at day 90, Outcome 4: Illness severity score" data-id="CD010612-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: death or nonârecovery of kidney function at day 90, Outcome 4: Illness severity score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: recovery of kidney function, Outcome 1: Recovery of kidney function by AKI aetiology" data-id="CD010612-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: recovery of kidney function, Outcome 1: Recovery of kidney function by AKI aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: recovery of kidney function, Outcome 2: Recovery of kidney function by definition of early KRT Initiation" data-id="CD010612-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: recovery of kidney function, Outcome 2: Recovery of kidney function by definition of early KRT Initiation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010612-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/urn:x-wiley:14651858:media:CD010612:CD010612-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: recovery of kidney function, Outcome 3: Recovery of kidney function by KRT modality" data-id="CD010612-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_t/tCD010612-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: recovery of kidney function, Outcome 3: Recovery of kidney function by KRT modality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/media/CDSR/CD010612/image_n/nCD010612-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010612-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Early versus standard initiation of kidney replacement therapy (KRT) in patients with acute kidney injury (AKI)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Early versus standard initiation of KRT in patients with AKI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI<br/><b>Setting:</b> intensive care unit<br/><b>Intervention:</b> early initiation<br/><b>Comparison:</b> standard initiation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants (RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard initiation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with early initiation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death at day 30</b><br/>Â  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>385 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>12 fewer per 1000<br/>(50 fewer to 35 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.97<br/>(0.87 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4826 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death after 30 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>457 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 fewer per 1000<br/>(37 fewer to 32 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.99<br/>(0.92 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4534 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death or nonârecovery of kidney function</b> </p> <p><b>Time frame: day 90</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>468 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>42 fewer per 1000<br/>(122 fewer to 51 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.91<br/>(0.74 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4011(6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recovery of kidney function</b> </p> <p><b>Patients free from KRT according to ITT analysis (all patients)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>493 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 more per 1000<br/>(30 fewer to 108 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.07<br/>(0.94 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4717 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: hypophosphataemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>42 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 more per 1000<br/>(14 more to 61 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.80<br/>(1.33 to 2.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2927 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ââââ<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>81 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>44 more per 1000<br/>(23 more to 69 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.54<br/>(1.29 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3864 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ââââ<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events: cardiacârhythm disorder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>54 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19 more per 1000<br/>(2 more to 41 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.35<br/>(1.04 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4483 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ââââ<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 more per 1000<br/>(0 fewer to 25 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.33<br/>(1.00 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4252 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of stay in ICU</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Mean length of stay in ICU was 1.01 days less with early initiation (1.6 less to 0.42 less) compared to standard initiation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4240 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of stay in hospital</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean length of stay in hospital was 2.45 days less with early initiation (4.75 less to 0.14 less) compared to standard initiation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4589 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Imprecision: due to the CI crossed the threshold for clinically meaningful effects </p> <p><sup>2</sup> Inconsistency: due to heterogeneity </p> <p><sup>3</sup> Indirectness: critically ill patients with AKI in RKT have high shortâterm risk of death; death is a competing end point for kidney recovery at day 90 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Early versus standard initiation of kidney replacement therapy (KRT) in patients with acute kidney injury (AKI)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010612-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Subgroup analyses: early versus standard initiation of kidney replacement therapy (KRT) in patients with acute kidney injury (AKI)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Early versus standard initiation of KRT in patients with AKI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> AKI<br/><b>Setting:</b> intensive care unit<br/><b>Intervention:</b> early initiation<br/><b>Comparison:</b> standard initiation </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants (RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with standard initiation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk difference with early initiation</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death by AKI aetiology: nonâsurgical causes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>383 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 more per 1000<br/>(23 fewer to 34 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/>(0.94 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4461 (9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death by AKI aetiology: surgical causes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>408 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>143 fewer per 1000<br/>(282 fewer to 147 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/>(0.31 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kidney recovery function</b> <b>by KRT: continuous KRT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>355 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>149 more per 1000<br/>(4 fewer to 365 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.42<br/>(0.99 to 2.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>583 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kidney recovery function</b> <b>by KRT: continuous and intermittent KRT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>520 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>21 fewer per 1000<br/>(47 fewer to 10 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/>(0.91 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4134 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>KRT</b>: kidney replacement therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Imprecision: due to the CI crossed the threshold for clinically meaningful effects </p> <p><sup>2</sup> Inconsistency: due to heterogeneity </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Subgroup analyses: early versus standard initiation of kidney replacement therapy (KRT) in patients with acute kidney injury (AKI)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/full#CD010612-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010612-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Early versus standard initiation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Death at day 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Death after 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Death or nonârecovery kidney function at day 90 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Patients free from KRT according to ITT analysis (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.94, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Survivors free from KRT according to ITT after 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.97, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.90, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Hypophosphataemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2927</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.33, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.29, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Cardiacârhythm disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.04, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.00, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.6 Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.7 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.20, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Length of stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Length of stay in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â1.01 [â1.60, â0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Length of stay in hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â2.45 [â4.75, â0.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Early versus standard initiation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010612-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Subgroup analysis: death</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Death by AKI aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Patients with AKI related to nonâsurgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Patients with AKI related to surgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.31, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Death by KRT initiation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Initiation according KDIGO stage 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Initiation according to KDIGO3, AKI RIFLEâF stage and AKIN3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Initiation according other criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.86, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Death by KRT modality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Continuous KRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Continuous and intermittent KRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Death by illness severity score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Sequential Organ Failure Assessment (SOFA) score &gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.75, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Sequential Organ Failure Assessment (SOFA) score â¤ 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Subgroup analysis: death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010612-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span>Â <span class="table-title">Subgroup analysis: death or nonârecovery of kidney function at day 90</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 AKI aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Nonâsurgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.97, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Surgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.33, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 AKI criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 KDIGO stage 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 KDIGO stage 3/RIFLEâF AKIN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Other criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.07, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 KRT modality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Continuous KRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.33, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Continuous and intermittent KRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.97, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Illness severity score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Sequential Organ Failure Assessment (SOFA) score &gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.62, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Sequential Organ Failure Assessment (SOFA) score â¤ 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.97, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>Â <span class="table-title">Subgroup analysis: death or nonârecovery of kidney function at day 90</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010612-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span>Â <span class="table-title">Subgroup analysis: recovery of kidney function</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Recovery of kidney function by AKI aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 AKI related to nonâsurgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 AKI related to surgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.78, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Recovery of kidney function by definition of early KRT Initiation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Initiation according KDIGO stage 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.86, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Initiation according KDIGO stage 3/RIFLEâF AKIN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Initiation according to other criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.95, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Recovery of kidney function by KRT modality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Continuous KRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.99, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Continuous and intermittent KRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span>Â <span class="table-title">Subgroup analysis: recovery of kidney function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010612.pub3/references#CD010612-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010612.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010612-note-0016">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="fa#CD010612-note-0012">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="fr#CD010612-note-0014">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="hr#CD010612-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD010612-note-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD010612-note-0010">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="ko#CD010612-note-0007">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="ms#CD010612-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010612-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD010612-note-0008">PortuguÃªs</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010612-note-0006">ç¹é«ä¸­æ</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright Â© 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">Â Â Facebook</a> <a class="a2a_button_x share-button">Â Â X(Twitter)</a> <a class="a2a_button_whatsapp share-button">Â Â WhatsApp</a> <a class="a2a_dd share-button">Â Â View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010612\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010612\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010612\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010612\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010612\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010612.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010612.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">EspaÃ±ol</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">ÙØ§Ø±Ø³Û</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">FranÃ§ais</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">à¤¹à¤¿à¤¨à¥à¤¦à¥</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">æ¥æ¬èª</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">íêµ­ì´</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">PortuguÃªs</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Ð ÑÑÑÐºÐ¸Ð¹</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">RomÃ¢nÄ</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">à®¤à®®à®¿à®´à¯</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">ç¹é«ä¸­æ</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">ç®ä½ä¸­æ</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010612.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010612.pub3/full/es">EspaÃ±ol</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010612.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727869773"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010612.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727869777"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010612.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb6991f2d9368',t:'MTc0MDcyNzg3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 